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Abstract
GSK3β regulates Epithelial-Mesenchymal-Transition and Cancer Stem Cell properties
and is a novel drug target for Triple-Negative Breast Cancer.
Geraldine Vidhya Raja, MS.
Advisory Professor: Sendurai Mani, Ph.D.
Triple-Negative breast cancers (TNBCs) are highly aggressive and lack the expression of
Estrogen Receptor (ER), Progesterone Receptor (PR) as well as Human Epidermal Growth
Factor Receptor (HER2). Consequently, patients diagnosed with TNBCs have poor overall- and
disease-free survival rates compared to other subtypes of breast cancer due to lack of targeted
therapies as well as de novo or acquired chemoresistance, disease recurrence, and lack of
targeted therapy. Hence it is critical to identify novel targets to treat TNBCs. TNBCs are
characterized by the presence of mesenchymal-like cells, which is indicative that EMT (epithelialmesenchymal-transition) plays an important role in the progression of this disease. EMT has also
been implicated in chemoresistance, tumor recurrence and generation of cancer stem cells
(CSCs). The Wnt signaling pathway has been determined to be one of the major players in EMT
and CSCs. Therefore, we analyzed patient survival data to determine a correlation between the
expression of Wnt components and overall survival. Of the several possible players, higher
expression of GSK3β correlated with poorer overall patient survival. In support of this observation,
we identified a GSK3β inhibitor, BIO, in a drug screen as one of the most potent inhibitors of EMT.
Since TNBCs are enriched with mesenchymal-like cells, we treated mesenchymal cell lines with
the GSK3β inhibitors and found that GSK3β inhibitors were among the few drugs that could
selectively kill mesenchymal-like TNBC cells compared to epithelial-like breast cancer cells. To
determine if GSK3β inhibitors specifically target mesenchymal-like cells by affecting the CSC
population, we employed the mammosphere assay and analyzed the CD44hi/24lo population of
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these cell lines. We found that GSK3β inhibitors indeed decreased the CSC properties of the
mesenchymal-like cell lines, and also decreased the expression of mesenchymal markers.
Inhibition of GSK3β decreased the migratory properties suggesting that the inhibition of EMT by
GSK3β inhibitor could contribute to the inhibitory effect of GSK3β on the migratory potential of the
mesenchymal-like cells. Taken together, our studies demonstrate that GSK3β is a novel target
for TNBCs and suggest that the GSK3β inhibitors could serve as selective inhibitors of EMT and
CSC properties of the aggressive TNBCs, and may hence be ideal for combination treatment with
standard-of-care drugs for women with this deadly disease.
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Chapter 1 – TNBC and the potential role of EMT, CSCs and
GSK3β.
1A.

Introduction to Triple-Negative Breast Cancer (TNBC).

Breast cancer is one of the leading causes of death among women and is second only to lung
cancer. Breast cancer affects 1 in 8 women in the United States [1]. Breast cancers are
molecularly classified into various subtypes. Primarily, breast cancers are classified based on the
expression of Estrogen Receptor (ER), Progesterone Receptor (PR) and ERBB2 (HER2) using
immunohistochemical analysis. The Triple-Negative Breast Cancers (TNBCs) are breast cancers
that do not express elevated levels of ER, PR or HER2 genes. TNBCs account for 15-20% of the
newly diagnosed breast cancer cases. Most of the TNBCs are diagnosed in young patients and
the disease is at an advanced stage by the time it is diagnosed [2]. TNBC tumors are usually
larger in size, are of higher grade, and have lymph node involvement at the time of diagnosis [3].
Immunohistochemically, there is no specific marker to pinpoint a TNBC, rather the diagnosis of
TNBC depends on the absence of the known markers, ER, PR and HER2.

An additional level of complexity that accompanies TNBCs, is the presence of intra-tumoral and
inter-patient heterogeneity [4]. TNBCs carry about 1.68 mutations per mega base of coding
regions which is approximately 60 mutations per tumor [4, 5]. With that being said, the mutation
burden is not uniform throughout the tumor and this is often accompanied by copy number
alterations in genes involved in several different pathways. Mutations are random events and
therefore, no two patients have the same mutations. So while all the TNBCs have similar gene
expression profile, there is high inter-patient heterogeneity. The genetic composition of the tumors
and thus their response to treatment is completely different from one patient to another.

1

TNBCs are classified as a single subtype, but the emergence of molecular profiling and other
“omics” technologies have shown a large amount of heterogeneity among these tumors. Of these
different breast cancer subtypes, the basal-like cancers mostly overlap with the TNBCs, but
despite the overlap are not synonymous [2]. The term basal-like indicates that these cancer cells
express genes like KRT5, KRT14 and KRT17 and EGFR that are normally expressed by normal
basal or myoepithelial cells [4]. More than 90% of basal-like breast cancers are TNBCs. Though
basal-like tumors have a high level of heterogeneity, they have distinct molecular characteristics
compared to other TNBCs [4]. In order to investigate the heterogeneity that exists in TNBC, the
histopathological characteristics and gene expression profiles of 97 TNBCs were analyzed and it
was found that the hierarchical cluster analysis also showed the presence of five distinct
subgroups [2, 6-8]. Another group investigated the gene expression profiles of 587 TNBCs. In
these analyses 6 different TNBC subtypes were identified: 2 basal-like-related subgroup (basallike 1 (BL1) and basal-like 2 (BL2)), 2 mesenchymal-related subgroups (mesenchymal (M) and
mesenchymal stem-like (MSL)), one immunomodulatory subgroup (IM) and luminal androgen
receptor group (LAR) [3, 4, 9] (Figure 1).
In summary, TNBCs are highly aggressive breast cancers that have lower overall and disease
free survival rates as compared to the other types of cancer. The main reasons for the lower
survival rates are – absence of targeted therapy, tumor recurrence and chemoresistance, and
metastasis.

2

Triple Negative
Breast Cancer

Luminal Androgen
Receptor

Basal-like

Basal-like
1

Immunomod
ulatory (IM)

Mesenchymal
(M)

Mesenchymal
stem-like (MSL)

Basal-like
2

Figure 1 – Classification of triple negative breast cancers (TNBCs). TNBCs are breast
cancers that lack the expression of ER, PR, and HER2. TNBCs can be subdivided into
Luminal Androgen Receptor (LAR), Basal-like (Basal-like 1 and Basal-like 2),
Immunomodulatory, Mesenchymal, and Mesenchymal stem-like subtypes.

1A.a. Absence of targeted therapy for TNBC
Patients with TNBCs have relatively poorer prognosis as compared to other subtypes of breast
cancer. Currently chemotherapy is the only treatment option that is available for patients with
TNBCs irrespective of their stage [4], due to the lack of targeted treatment. [4]. As previously
mentioned, TNBC tumors do not express ER, PR or HER2 genes, all of which are molecular
targets of therapeutic agents used to treat breast cancer. Due to the extensive genetic and
molecular profiling studies several different targetable mutations have been identified [4]. In
addition to the mutations in P53 and PIK3CA gene, other actionable targets such as deletions of
PTEN or INPP4B genes and amplifications such as KRAS, BRAF, EGFR, FGFR1, FGFR2,
IGFR1, KIT and MET have been identified [4]. However, the actionability of these targets is yet to
be established because each tumor has multiple mutations which play major roles in several vital
intertwined pathways, thus making it difficult to predict the outcome of targeting these mutations.
Additionally, due to the intra-tumoral heterogeneity within TNBCs, a target that may affect one
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clonal population may not affect another clonal population thus giving rise to chemoresistance or
lack of response to targeted therapies.

1A.b. Contribution of tumor relapse and chemoresistance to TNBC-related fatality
In addition to lack of targeted therapy, the factor that increases the lethality of the TNBCs is the
risk of tumor recurrence and emergence of chemoresistance. Extensive research has rendered
breast cancers curable as long as it is discovered at an early stage. However, many a times the
disease-free survival is disrupted by the reappearance of the tumor at the primary or a secondary
site. Recurrence is one of the major reasons for breast cancer-related fatalities [10, 11]. The rate
of recurrence of breast cancer is estimated to be 15-20% [12, 13]. Of these, 60-80% of tumor
recurrences occur within 3 years, but the chances of recurrence exist up to 20 years after the
diagnosis of the disease [9]. Therefore several studies have been undertaken to discover a
predictor or pattern that might indicate the probability of recurrence and thus aid in preventing the
relapse of the disease [10].

In an effort to predict recurrence, the correlation between subtype of tumor and the disease
relapse has been examined. It has been observed that the rate of recurrence is higher for the ERnegative subtype of breast cancer in the first 5 years following the diagnosis and treatment [10,
14]. As discussed earlier, the aggressive TNBCs have a higher rate of recurrence both at the
primary and secondary site as compared to tumors that are ER-positive. It was also found that
the ER+ and PR+ patient had lower rate of tumor recurrence as compared to TNBCs [10, 15].
These studies indicate the importance of molecular classification of tumors in the clinics both for
the treatment and for taking preventive measures.

4

There are mainly 2 hypotheses to explain tumor recurrence. The first hypothesis is that the
recurrence exists before the primary diagnosis and may have been detected as a multifocal tumor.
The second hypothesis is the wound oncogene wound healing (WOWH) hypothesis [10, 16]. The
WOWH hypothesis proposes that there is an intricate link between stress and oncogenesis. The
stress could be either physical like radiation, chemical, like carcinogens or biological like
inflammation, trauma, presence of pre-cancerous lesions, oncogenes and the progression of
cancer [16]. When a tumor is diagnosed and treated, the region of treatment is damaged and
faces a harsh environment followed by inflammation [10, 16]. This could in turn aggravate an
existing injured cell to undergo transformation or injure new cells and create a new wound. Thus,
depending on the presence of a pre-existing wound or creation of a new wound and the different
insults weathered by the body in question, the tumor recurs [10, 16].

The causes of breast cancer recurrence are still unknown but following are the molecular factors
which have been found to contribute to the tumor recurrence including epithelial-mesenchymaltransition (EMT), cancer stem cells (CSCs), Wnt signaling, circulating tumor cells (CTCs) and few
other factors such as β1 Integrin, notch signaling, hedgehog signaling, and miRNAs [12]. Until a
clear insight is gained into the mechanism of breast cancer recurrence, it would be impossible to
develop targeted therapies to prevent breast cancer recurrence. However, few drugs such as
bisphosphonates and aromatase inhibitors and natural compounds such as curcumin,
sulforaphane, isoflavones, EGCG and resveratrol are being investigated for their potency in
preventing breast cancer recurrences [10, 17].
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1B.

TNBCs are highly metastatic

As mentioned above, metastasis and not the primary tumor is the principle cause of cancerrelated fatalities. More than 90% of cancer-related deaths are due to the metastasis and therefore
it is imperative that we find a means of disrupting or reverting this lethal process [18, 19].
Metastasis is a cascade of steps in which cancer cells from the primary tumor dissociate, invade
the surrounding connective tissue and intravasate into the vasculature to enter circulation. These
tumor cells, now called the circulating tumor cells (CTCs), find anchor on the endothelium and
extravasate to enter the secondary site where they form micrometastases. These subsequently
establish a favorable niche where they proliferate to form macrometastases which is what is
detected as the metastatic lesion [20]. Usually, these metastatic lesions are formed in vital organs
or regions that are difficult to surgically resect thus further endangering the life of the patient.
TNBCs have 4 times more the tendency to metastasize to the visceral organs as compared to the
other subtypes of breast cancers [21, 22]. Each step of the metastatic cascade is essential for the
cells to successfully metastasize and the ability of the cell to complete each of these steps
determines its metastatic potential. Therefore each step serves as an opportunity to impede and
halt the process. Understanding these processes in depth is vital for reducing the metastatic
potential of the cancer cells. The steps of the metastatic cascade are as follows;
Invasion - Normally, the tumor is comprised of epithelial cells that have polarity and a basement
membrane along with providing the architectural support also provides signaling molecules that
help the cells determine and retain their polarity [18, 23]. When the cells try to break free from the
bonds and polarity, the signaling and the basement membrane serve as a barrier [18]. In the
mammary gland, the myoepithelial cells and the alterations in the stiffness of the connective tissue
and several other factors serve as a deterrent for the invasion of the basement membrane [18,
24, 25]. The invading cancer cells might utilize either the EMT-mediated mesenchymal program
or the amoeboid invasion program [18, 26]. The induction of EMT results in the loosening of the
6

cell-cell bonds and also enhances the secretion of matrix metalloproteases (MMPs) and other
enzymes that aid in the breakdown of the basement membrane and the connective tissue limiting
the tumor mass. Once the cells have breached the basement membrane, they come in contact
with the stroma. The tumor-associated stroma may be inflamed or trying to heal the wound and
depending on the state of the stroma might contain fibroblasts, endothelial cells, mesenchymal
stem cells, adipocytes and immune cells. This creates a positive feedback loop where the
invading tumor cells condition the stroma to aid in metastasis and the inflamed stroma promotes
invasion of the cancer cells. TNBCs are associated with the presence of invasive edges and the
presence of lymphocytic infiltrates at these edges [27].

Intravasation – Intravasation is a process, where the cancer cells leave the primary site and
enter the 2 main circulatory systems of our body, the lymphatic system and the vasculature [18].
While the cells that enter the lymphatic system mostly serve for diagnostic purposes, the cells
that enter the vascular circulation are the ones that are primed to metastasize to a secondary
distant location [18, 19]. When the tumor cells intravasate, they and the assisting stromal and
immune cells secrete molecules such as transforming growth factor-β (TGFβ), Epidermal growth
factor (EGF) and colony-stimulating factor-1 (CSF-1) that alter the pericytes and weaken the
trans-endothelial barrier and allow the cells to invade [18, 28]. The other mechanism is the
formation of new blood vessels. As the tumors grow in size, they secrete vascular endothelial
growth factor (VEGF), MMP-1 and 2, cyclooxygenase-2 (COX2), epiregulin (EREG) that stimulate
the formation of new blood vessels that serve to supply oxygen and nutrition to the growing tumor
[29]. However, this neoangiogenesis leads to the formation of leaky vasculature due to weak
endothelial interactions and lack of pericytes which allows the entrance of the tumor cells into
circulation [18, 30].
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Circulation – Once the cancer cells intravasate and enter into circulation, they are known as
circulating tumor cells or CTCs. These tumor cells have to survive in the circulation. The first
major challenge is that capillaries are smaller in diameter than the tumor cells and this results in
CTCs getting trapped in capillaries [18]. The next challenge faced by them is the onset of anoikis.
Normal cells are anchorage dependent and when disconnected from the extracellular matrix,
anoikis sets in and leads to cell death. However, CTCs avoid anoikis by metabolic reprogramming
and upregulating suppressors of anoikis like Tropomyosin receptor kinase B (TrkB) [31-33].
Another theory proposed is that several of the CTCs get trapped in capillaries or exit circulation
and extravasate before anoikis could be triggered in cells [18]. The other challenges that the CTCs
face are the circulating immune cells and the hemodynamic shear that can lead to the disruption
of the cell. In order to overcome these, the CTCs have been found to attach to platelets in
circulation and form large emboli that cannot be detected by the immune cells and to tolerate the
shear force [34].

Extravasation – The CTCs that survive the circulation and get trapped in the capillary beds at
different locations have to enter back into the tissues in order to form metastatic lesions. There
are mainly 2 ways in which this is achieved. The trapped cells can proliferate and form colonies
and these colonies then secrete factors that can help break down the endothelial barrier and
provide access to the secondary site of metastasis. The primary tumor cells and the CTCs
themselves secrete factors such as angiopoietin-like-4 (Angptl4), EREG, MMPs, VEGF etc. that
increase the permeability of the vasculature [35]. Additionally, certain immune cells such as
inflammatory monocytes have been known to enhance extravasation of breast cancer cells into
the lungs [36].
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Micrometastasis – The cells that have extravasated have to then adapt to the new
microenvironment which is usually different from that of the primary site. However, it has been
observed that the micrometastatic niche is primed before the arrival of the cancer cells to the
metastatic site [37]. The primary tumor has been found to secrete factors which include Lysyl
Oxidase (LOX) [37]. LOX stimulates the production of fibronectin which in turn attracts VEGF
receptor-positive hematopoietic progenitor cells [37, 38]. These cells secrete MMPs which breaks
down the ECM at the site of future metastasis. The breakdown of the ECM is accompanied by
the release of chemoattractants such as stromal cell derived factor 1 (SDF-1) [37]. While these
priming processes take place at the site of metastasis, the homing tumor cells also make
alterations in their signaling to adapt to the new environment. Breast cancer cells that form
micrometastasis in the bone have been observed to activate Src signaling and this promotes cell
viability in the bone microenvironment without affecting the homing capacity of these cells. While
suppressing Src signaling decreased metastatic lesions in the bone, it did not prevent the same
breast carcinoma cells from colonizing the lungs [18, 39].

Macrometastasis – Macrometastasis is a process in which the micrometastatic colonies
proliferate to form diagnosable colonies. Not all the micrometastatic colonies form
macrometastasis. The unfavorable microenvironment can serve as a deterrent for the growth of
these colonies. Many of these colonies either die slowly over a long period to time due to lack of
favorable stimuli or remain dormant and just stay viable such that there is no alteration in the cell
number. In the case of breast cancer, it has been observed that cells that are unable to stimulate
Focal Adhesion Kinase (FAK), integrin β1 and Src pathways are unsuccessful in forming
metastatic colonies [40-42]. Additionally, absence of stimulating factors in the microenvironment
could also contribute to this quiescence. However, some of the factors secreted by the primary
tumors may serve as stimulants for the dormant metastatic colonies [43, 44].
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Another reason for the inability of the micrometastatic colonies to grow into macrometastases is
the low proliferative rate of these cells as compared to the high apoptotic potential of these cells.
This has been attributed to the lack of neoangiogenesis in these lesions as a result of which they
are deprived of both oxygen and nutrition [45]. One of the means of overcoming these barriers, is
by the induction of EMT. As mentioned previously, the cells that have undergone EMT gain stemlike properties which enable them to have immense proliferative and self-renewing potential which
aids these cells in the micrometastatic colonies to proliferate and form macrometastatic colonies.

Another factor that determines the ability of the cells to colonize and form metastatic lesions is
their ability to turn on the genes required to make them compatible with the microenvironment at
the metastatic site. This fact was discovered by Paget when he put forward the seed and soil
hypothesis [46]. Not all the cancer cells can survive in all the microenvironments that they home
to. Only the ones that are capable of adapting to the new microenvironment survive and colonize
the secondary metastatic site. As a proof of this concept, it has been observed that the genetic
and epigenetic profile of the breast cancer cells that metastasize to the bone is dramatically
different from that of the cells metastasizing to the brain, lung or liver [47-50]. However, the genetic
and epigenetic profile is not determined by the destinated organ alone. For example, the genetic
and epigenetic makeup of the breast cancer cells colonizing the bone is very different from the
profile of prostate cancer cells which metastasize to the bone [18].

Due to the high complexity of this cascade, only very few of the cells that are disseminated from
the primary tumor actually reach their target and establish macrometastasis. It is these few cells
that need to be targeted and inhibited from successfully completing this cascade. One of the
crucial events that enhances the metastatic potential of the cancer cells is the process of EMT.
Hence, understanding and targeting EMT is essential to inhibit metastasis. In summary, TNBCs
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are highly aggressive subtype of breast cancers. This tumor subtype has high similarity to basallike breast cancers. Due to the absence of targeted therapy, TNBCs are difficult to retreat. These
tumors predominantly develop resistance to chemotherapy also develop metastasis at high rate.
As these tumors are highly enriched for cells with EMT/CSC properties, targeting EMT may be a
potential means of inhibiting TNBCs.

1C.

Epithelial-Mesenchymal-Transition is a vital player in the chemoresistance,

tumor relapse and metastasis of TNBCs.
Epithelial-mesenchymal-transition is a dynamic process that was initially discovered by
Dr.Elizabeth Hay in 1980 [51, 52]. She observed a phenomenon in which the epithelial cells
acquire mesenchymal properties in the primitive streak of a chick embryo and named it
mesenchymal transformation [51, 52]. This process was later renamed as the epithelialmesenchymal-transition to reflect its transient nature [52]. During the process of EMT, an
epithelial cell which is normally attached to the basement membrane in an apical-basal
orientation, gains mesenchymal characteristics such as a spindle-shaped morphology, increased
migratory and invasive potential, resistance to apoptosis and senescence and expresses
significantly greater amount extra-cellular matrix genes [52, 53] (Figure 2). EMT is a wellestablished central player in embryonic development, wound healing and tumor progression and
as a result a lot of effort has been devoted to unraveling the mechanism and regulation of EMT.
In breast cancer, circulating tumor cells (CTCs) isolated from peripheral blood of patients, share
several properties with mesenchymal cells indicating that these cells have undergone EMT [5355]. Furthermore, basal-like and claudin-low breast cancers are transcriptionally similar to
mesenchymal cells [56-58].
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EMT

Epithelial Properties

Mesenchymal Properties

•

Cobble-stone morphology

•

Spindle Shaped

•

Tight cell-cell adhesion

•

Loss of cell-cell adhesion

•

Differentiated

•

Less differentiated

•

Less Invasive

•

Highly invasive

•

Cancer stem cell properties

Figure 2 – Epithelial to mesenchymal transition (EMT). EMT is the process that induces the
phenotypic alteration of epithelial cells to mesenchymal cells as a result of which they gain
enhanced migratory potential and stem-like properties listed above, which aids in the
metastatic cascade.

EMT is also closely linked to cancer stem cells (CSCs) [59]. Cancer stem cells are cells that have
unlimited self-renewal potential and are capable of giving rise to both undifferentiated and
differentiated daughter cells. FOXC2, a transcription factor was demonstrated to be an important
EMT marker as well as an indicator of CSC properties, thus suggesting the EMT and CSCs are
intricately linked [59, 60].

All these changes effected by EMT involve a complex cascade of signaling that orchestrates this
smooth transition. Several transcription factors, cell surface markers, cytoskeletal organization
proteins, and micro-RNAs (miRs) play a pivotal role in choreographing this intricate process.
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However, this signaling can be inhibited or reversed which in turn induces the process known as
the mesenchymal-epithelial-transition or MET [52]. This ability of the cells to switch back and forth
between the epithelial and the mesenchymal phenotype is known as plasticity [52]. The presence
of this plasticity in TNBCs enhances their metastatic potential. Understanding the regulation of
EMT will facilitate the identification of regulatory nodes that can be targeted to inhibit metastasis
of TNBCs.

1C.a. Regulation of EMT
Induction of EMT is accompanied by an alteration in gene expression in order to help the cells
gain mesenchymal properties. However, these changes in the gene expression are not uniform
and differ depending on the factor inducing EMT and the tissue in which the transition is taking
place. While the post-translational modifications disrupt epithelial cell adhesions and polarity, the
presence of the epithelial cell adhesion molecules will promote re-assembly of these adhesions.
Therefore, in order to prevent de novo formation of epithelial cell adhesions and acquisition of
polarity, the transcription of these molecules have to inhibited and replaced with molecules that
form mesenchymal adhesions. E-cadherin is repressed in all cells undergoing EMT regardless of
the cell type or the EMT-inducing factor [51]. During the cadherin switch, which is considered to
be one of the hallmarks of EMT, the expression of N-cadherin is upregulated [53, 61]. N-cadherin
connects to the actin cytoskeleton via β-catenin and α-catenin, forms homotypic interactions with
other mesenchymal cells which facilitates migration, and interacts with receptor tyrosine kinases
such as PDGF and FGF receptors [62-64].

The composition of the extracellular matrix also undergoes a dramatic change. There is increased
expression of mesenchymal ECM molecules such as vimentin and fibronectin and decrease in
the expression of epithelial ECM molecules such as keratins [65]. Additionally, the expression of
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cellular molecules that interact with the ECM is also altered. To choreograph this transition,
several different transcription factors, non-coding RNAs, alternative splicing, composition of the
microenvironment, ligands and growth factors contribute to ensure the effective switch from the
epithelial to the mesenchymal phenotype.

There are several transcription factors that are potent inducers of EMT. The mechanism by which
they induce EMT has been well-studied and established. Some of the most well-studied
transcription factors that regulate EMT include Snail, Slug, Zeb1, Twist and FOXC2 [51, 60, 66,
67]. The Snail family of transcription factors is made up of 2 sub-families, the Snail family that
includes Snail and Slug and the other sub-family is Scratch [51, 68, 69]. Of these different Snail
family members, only Snail and Slug have been implicated in EMT and therefore in development,
fibrosis and cancer [51].

Numerous EMT inducers such as TGFβ, Wnt, Notch and receptor tyrosine kinases activate the
expression of Snail [51, 66]. Snail induces the mesenchymal phenotype by the repression of Ecadherin. Snail binds to the E-cadherin promoter and recruits epigenetic modifier, Polycomb
Repressive Complex II (PRC2) which comprises methyltransferase enhancer of Zeste homologue
2 (EZH2), G9a and suppressor of variegation 3-9 homologue 1 (SUV39H1), the co-repressor
SIN3A, histone deacetylases 1, 2, and 3 and Lys-specific demethylase 1 (LSD1) [70-75]. All these
components of the complex work together to ensure the epigenetic inhibition of E-cadherin [51].
Snail also induces the expression of mesenchymal markers such as fibronectin, N-cadherin,
collagen, MMPs, Twist and Zeb1 [51].
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One of the primary regulators of Snail is glycogen synthase kinase 3 β (GSK3β) [76]. GSK3β is a
multifaceted serine threonine kinase that has regulatory functions in several vital cellular
processes such as cell cycle, apoptosis, migration, metabolism etc. [77]. Several signaling
pathways regulate Snail function via their effect on GSK3β. The Wnt, Notch, NFkB and AKT-PI3K
signaling pathways inhibit GSK3β thereby promoting the function of Snail [51, 78-80].
Phosphorylation of Snail by (small C-terminal domain phosphatase 1) SCP1 interferes with the
ability of GSK3β to phosphorylate Snail thereby stabilizing it [51, 81]. Phosphorylation by p21
Activated Kinase 1 (PAK1) and Large Tumor Suppressor 2 (LATS2) promotes nuclear localization
of Snail [82, 83]. The players that negatively regulate Snail include (Protein Kinase D1) PKD1 and
p53, which promote the nuclear export, and the ubiquitination and degradation of Snail
respectively [51, 84].

Along with Snail, Zeb1 is also a potent inducer of EMT [66]. Zeb1 recognizes the E-Box for
binding. It can act both as an activator and as a repressor depending on the co-factor present [51,
66]. Zeb1 represses the expression of E-cadherin in the presence of the co-repressor
Switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling protein BRG1 rather than in the
presence of its usual co-repressor, the C-terminal binding protein (CTBP) [85]. Zeb1 expression
is upregulated during EMT by Snail or by the activity of ligands such as TGFβ and Wnt [86]. The
expression of Zeb1 is also regulated by miR200 which is associated with the epithelial phenotype
[87].

The other transcription factors influencing the process of EMT include the bHLH transcription
factors, the FOX family and the GATA family of transcription factors. FOXC2 is one of the
transcription factors that has been reported to be upregulated following EMT regardless of the
pathway via which EMT is induced [60]. Additionally, inhibition of FOXC2 is sufficient to inhibit
EMT induced by potent EMT inducers such as Snail, Twist, Goosecoid and TGFβ [60].
15

Overexpression of FOXC2 has been shown to induce EMT in human mammary epithelial (HMLE)
cells and FOXC2 has been shown to be responsible for the CSC properties of the cells that have
undergone EMT [60, 88, 89]. Of the several members of the bHLH transcription factor family, E12,
E47, Twist 1, Twist 2 and inhibitor of differentiation (ID) have been shown to play a role in EMT
[66]. As tumors progress and grow, certain regions undergo hypoxia, which turns on the
expression of HIF1α which transcriptionally upregulates the expression of Twist and induces EMT
in the tumor. The next layer of regulation of Twist depends on the interacting proteins. Twist
functions as a dimer and can form homo- or heterodimers with E12, E47 or ID. Dimerization with
ID inhibits Twist function and therefore ID needs to be repressed for the effective functioning of
Twist [90]. TGFβ can cause repression of ID thus promoting the transcriptional activity of Twist
[91]. Twist is also capable of recruiting epigenetic modifiers to the promoter regions of its target
genes and modifying their expression. Twist is capable of repressing the expression of E-cadherin
in multiple ways independent of Snail [86, 92, 93]. The other transcription factors involved in the
induction of EMT includes members of the forkhead box (FOX), GATA and Sry box (SOX)
transcription factors [94, 95].

Next to transcription factors, the growth factors are most frequently studied in association with
EMT. Several growth factors including, EGF, FGF, HGF, IGF, PDGF, TGFβ, and Wnt have been
examined for their effect on EMT. Fibroblast growth factor (FGF) induces EMT in epithelial cells
by upregulating the expression of Slug, α2β1 integrin, and MMP13 and by destabilizing the
desmosomes [96, 97]. Hepatocyte growth factor (HGF) binds and activates the c-Met receptor
which is also known as the HGF receptor (HGFR). HGF was identified as a “scatter factor” due to
its ability to transform kidney epithelial cells to fibroblast-like motile cells. HGF induces EMT by
stimulating the expression of Snail or Slug depending on the type of cell and requires the activity
of ERK-MAPK pathway [98]. HGF also represses the expression of desmoplakin which in turn
destabilizes the desmosomes [99]. In certain breast cancer cells, Insulin-like growth factor 1
16

(IGF1) has been observed to induce EMT, which is characterized by an increase in the expression
of N-Cadherin, vimentin and fibronectin and decrease in the expression of E-cadherin [100]. The
Snail-NFκB signaling pathway is activated in these breast cancer cells [100]. The IGF receptor
(IGFR) interacts with E-cadherin to form a complex which is disrupted upon activation of the
receptor by the ligand IGF1 [101]. This disruption of the E-cadherin IGFR complex enhances the
motility of the cells. However, the response elicited by IGF1 is not the same in all the cell types.
In other cell lines, IGF1 was seen to upregulate the expression of Zeb1 in a PI3K and MAPK
dependent manner [102]. Epidermal growth factor (EGF) is another growth factor that has been
known to induce EMT in breast cancer cells. Exposure to EGF leads to the endocytosis of Ecadherin and upregulation of Snail and Twist [103]. MMPs are upregulated and the ERK-MAPK
pathway is activated in breast cancer cells that have been exposed to EGF [104]. Platelet-derived
growth factor (PDGF) induces EMT by stimulating the nuclear localization of β-catenin and
repression of E-cadherin [105].

TGFβ family of ligands consists of 3 TGFβ ligands, 2 activins, bone morphogenetic proteins
(BMPs) and several other ligands [106]. TGFβ3 has been implicated in the induction of EMT
during development whereas TGFβ1 has been attributed with the role of inducing EMT during
wound healing, in cancer and fibrosis and also in endothelial-mesenchymal-transition (EndMT)
[107-111].

TGFβ ligands bind to tetrameric transmembrane receptors to activate TGFβ signaling [112]. When
the ligand binds to the receptor containing TGFβRII, it phosphorylates and activates TGFβRI
which turns on SMAD signaling by phosphorylation of the C-termini [113]. Activated SMAD2
and/or 3 interact with activated SMAD4 to form a trimer which translocates to the nucleus to alter
the transcription of mesenchymal genes such as fibronectin and collagen αI [112]. Depending on
the other SMADs that are activated, SMAD4 can bind to SMAD1 or SMAD5. If the inhibitory
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SMAD6 or 7 bind to the receptors, the TGFβ signaling is interrupted [114]. Thus the activation of
the TGFβ signaling involves a delicate interplay of ligands binding to the receptors and the
presence of the appropriate SMADs to relay the signal. In addition to spurring EMT by promoting
the transcription of the target genes, the components of the TGFβ pathway also indirectly aid the
function of other EMT inducers. For example, Snail in the presence of SMAD3 upregulates the
transcription of its target genes whereas the expression of Slug is indirectly upregulated by the
SMAD3 mediated increase in the expression of myocardin-related transcription factor (MRTF)
which transcribes Slug [115]. SMAD3/4 complex can bind and regulate the transcriptional activity
of the Zeb1 transcription factor [116]. They also interact with activating transcription factor 3
(ATF3), which enables the repression of ID, facilitating the activity of Twist. Additionally, they can
also upregulate the expression of HMGA2 [116].

TGFβ also functions independently of SMADS to promote EMT. The TGFβ receptor interacts with
and phosphorylates partition defective (PAR6), which is an integral part of the tight junction
responsible for maintaining the cell polarity [117]. This aids in dissolving the junction which is one
of the very first steps in early EMT. It also plays a role in activating the RHO pathway which
enhances cell mobility by facilitating the formation of lamellipodia and filopodia [118]. The
activation of the PI3K-AKT pathway is essential for the TGFβ induced EMT to such an extent that
inhibiting PI3K prevents the induction of TGFβ mediated EMT [119]. TGFβ induces Akt-mediated
phosphorylation of heterogeneous nuclear ribonucleoprotein E1 (hnRNPE1), which releases it
from the 3’ untranslated region of disabled 2 (DAB2) and interleukin (IL) like EMT inducer (ILEI)
mRNA, which allows their translation and promotes EMT [120]. The BMPs play a role in both EMT
and MET and of the many BMPs, BMP 2, 4 and 7 promote EMT [121, 122]. Like the TGFβ
signaling pathway, the Wnt signaling pathway is one of the well-studied pathways that plays an
important role in development and EMT [123, 124].
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1C.b. Wnt signaling has been implicated in EMT and CSC enriched TNBCs.
The Wnt signaling pathway is one of the well-studied pathways that play an important role in
development and disease [123, 124]. The Wnt signaling pathway is named after the Wnt1 gene,
homolog of Wingless gene in flies, which was shown to regulate polarity during development.
There are 19 Wnt genes in humans and most mammals, which are classified into 12 subfamilies
[125]. All the Wnt genes encode for secreted cysteine-rich, 40kDa glycoproteins which share
about 35-85% homology. Of these 19 Wnts, 7 ligands have been found to be expressed in mouse
mammary tissue and Wnt 2, 3, 4, 5A, 7B, 10B, 13 and 14 are expressed in human mammary
gland [125-127]. Due to their structural similarity, Wnt ligands are redundant in function. The Wnt
ligands bind to a heterodimeric receptor. The cell surface receptor that binds the Wnt ligands is
comprised of a seven transmembrane domain protein belonging to the Frizzled (Fzd) family and
a LDL receptor-related protein (LRP 5/6) [124, 125]. There are at least 10 known Frizzled proteins
in humans and any of these can bind to any of the Wnt ligands to activate the downstream
signaling [124]. When Wnt binds to the cysteine-rich part of the Fzd’s extracellular domain, it
forms a trimeric complex with Fzd and LRP which induces a conformational change in the
cytoplasmic domain of LRP 5/6 [125]. Based on the downstream signaling, the Wnt pathway has
been classified as the canonical or the non-canonical pathway [124, 125]. Of the 2 signaling
pathways the canonical signaling pathway is relevant to our studies and hence is described in
detail.

The canonical Wnt signaling, also known as the Wnt/β-Catenin signaling is the most studied of
the Wnt signaling pathways. β-Catenin has roles both in the cytoplasm and the nucleus of the
cell. In the cytoplasm, it forms complexes with E-cadherin and other proteins involved in
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maintaining cell-cell adhesion, thus aiding in the maintenance of tissue integrity [125]. In the
nucleus, it acts as a regulator of transcription [125]. When the Wnt signaling is off or the Wnt
ligand is absent, newly synthesized β-catenin is marked for destruction by the destruction
complex. The destruction complex is made up of scaffolding proteins, adenomatous polyposis
coli (APC) and Axin 1 or 2, and kinases casein kinase 1 (CK1) and glycogen synthase kinase 3β
(GSK3β). β-catenin is sequentially phosphorylated by CK1 followed by GSK3β, which marks it for
ubiquitination and ultimately for destruction by the proteasome. When Wnt signaling is activated,
cytoplasmic changes in LRP5/6 promotes its binding to Axin in the destruction complex. Fzd on
the other hand, binds to Disheveled (Dvl) which is an Axin-binding protein [124]. Both these
actions together prevents the destruction of β-Catenin, which starts accumulating in the cytoplasm
and enters the nucleus. When the Wnt signaling is inactive, TCF (T-cell factor) /Lef are bound by
a co-repressor called Groucho, which prevents transcription of their target genes [124]. When
Wnt is activated and β-catenin enters the nucleus, it displaces Groucho and facilitates the
interaction of TCF/Lef with co-activators such as B-cell lymphoma 9/legless (BCL9/LGS) and
Pygopus (pygo) and promotes the transcription of its target genes [124]. The target gene list for
the Wnt/β-catenin pathway has been growing since the day it was discovered and some of the
target genes such as cyclin D1 and c-myc have been identified as being tumor promoters [125].

In TNBCs and basal-like breast cancer Wnt signaling, both canonical and non-canonical
pathways, is commonly dysregulated and contributes to enhanced tumorigenesis and metastasis
[128-130]. Dyregulation of Wnt in TNBC patients was found to be associated with poor prognosis
and higher risk of developing lung and brain metastasis [128, 131, 132]. The aberrations in the
Wnt signaling pathway is evident from the fact that β-catenin nuclear localization, enhanced levels
of cyclin D1 in invasive TNBCs, and increased levels of DKK1, another Wnt/B-catenin target gene,
are observed [124]. In the nucleus, BCL9, a co-factor that binds and promotes β-catenin has
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been found to be upregulated in basal-like breast cancers, and LBH and SOX9 both of which are
β-catenin targets have been reported to be upregulated as well [124]. Immunohistological studies
have shown high levels of β-catenin to be present in either the cytoplasm and/or nucleus of breast
cancer tissue. In some of these cases, the increase in the expression of β-catenin was also
accompanied by elevated levels of cyclin D1, a β-catenin target, and this correlated with poor
survival [133-135]. These findings are also supported by the fact that elevated levels of β-catenin
protein were detected in tumor lysates using western blotting technique, and this served as a
molecular confirmation of the immunohistological observations [134]. Non-canonical Wnt
signaling has also been demonstrated to promote TNBC metastasis via the JNK pathway [128,
136]. TNBCs are highly enriched for CSCs which contribute to their higher rate of relapse and
chemoresistance and studies have shown that this effect can be attributed to the dyregulation of
Wnt signaling pathways in these CSCs [137]. These finding emphasize the need to target the Wnt
signaling pathway to inhibit EMT and CSC-mediated progression of TNBCs. Therefore, we
assessed the clinical significance of several key players of the Wnt signaling pathway using the
KMPlotter and our preliminary studies drew our attention to GSK3β which is a critical player not
only in the Wnt signaling pathway but also several other vital pathways that play a pivotal role in
governing and regulating the cells. Therefore we decided to take a deeper look into this ubiquitous
and multifaceted kinase, GSK3β.

1D.

Role of Glycogen Synthase Kinase 3β in tumor progression

Glycogen Synthase Kinase 3 (GSK3), ATP:Phosphotransferase E.C.2.7.1.37 is a serine
threonine kinase belonging to the CMGC (Cyclin-Dependent Kinases (CDKs), Mitogen Activated
Protein Kinases (MAPKs), Glycogen Synthase Kinases (GSKs), CDK-like Kinases (CLKs)) family
of kinases [138]. Kinases are a family of enzymes that catalyze the transfer of phosphate group
from adenosine triphosphate (ATP) to their target substrates [139]. Serine-threonine kinases
21

specifically transfer the phosphate group to either serine or threonine residue on the substrate
[139]. This phosphorylation can in turn regulate the stability, localization and function of the
substrate.

GSK3 was first isolated from the rabbit skeletal muscle [139, 140]. GSK3 is a highly conserved
kinase and orthologs of this kinase are expressed in plants, fungi, worms, flies, sea squirts, and
all the vertebrates [138]. Even species as far apart as humans and flies have 90% similarity within
the protein kinase domain [141]. GSK3 was first discovered for its ability to phosphorylate
glycogen synthase, the rate-limiting enzyme in the glycogen synthesis pathway and hence the
name glycogen synthase kinase [140]. At about the same time GSK3 was found to activate ATPMg-dependent form of type-1 protein phosphatase (Factor A) [140]. GSK3 was first isolated as a
complex with Factor A and was cloned based on partial peptide sequencing [142, 143]. Two
different cDNAs were isolated from rat brain and these corresponded to GSK3 alpha (GSK3α)
and GSK3 beta (GSK3β) [138, 143]. The 2 isozymes are coded on 2 different genes. GSK3α is
coded on chromosome 7 in mouse and on chromosome 19 in human and has molecular weight
of 51 kDa [143]. GSK3β, on the other hand, is coded on mouse chromosome 16 and human
chromosome 3 and has a molecular weight 47 kDa [143]. Although they are coded on different
genes, they have 98% similarity in the kinase domain but only 85% overall sequence homology
[143]. GSK3α has an extended glycine rich, 63 residues N-terminal region that might act as a
pseudosubstrate [138, 139]. Both the isoforms are conserved in most of the species except birds
which seem to have evolutionarily lost the expression of GSK3α [138]. A third isoform of GSK3,
GSK3β2 has been recently discovered to be expressed in the brain tissue [144, 145]. This splice
isoform is generated due to splicing between the exon 8 and 9 of GSK3β and results in the
introduction of 13 amino acids into the kinase domain of GSK3β [144, 145]. Though GSK3α and
GSK3β are highly conserved and have high level of homology, they are not functionally
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redundant. This was evident when the transgenic mouse, in which the exon 2 of GSK3β was
selectively deleted, was embryonic lethal due to extensive hepatocyte apoptosis, even after
having a fully functional GSK3α [139, 146]. Of the 3 isoforms, GSK3β is the well-studied isoform.
GSK3β is made up of 2 major domains. The β-strand domain is present in the N-terminus
spanning the amino acid residues 25-138 and the α helical domain occurs at the C-terminus from
amino acid residue 139 to 343 [146, 147]. The ATP binding domain is present at the interface of
the 2 major domains. Arg96, Arg180 and Lys205 form a small pocket that recognizes the priming
phosphorylation present on the primed substrates of GSK3β [146, 147].

GSK3β is a ubiquitously expressed gene and both isoforms are expressed in all mammalian
tissues. GSK3β is highly expressed in the brain, both in the neurons and the glia. The name is
very misleading as GSK3β was soon discovered to be associated with innumerable cellular
functions including metabolism, cell signaling, cellular transport, apoptosis, proliferation, gene
transcription, protein synthesis, stem cell renewal and differentiation, circadian rhythm, axial
orientation, patterning, response to DNA damage and migration [139].

GSK3β is involved in innumerable pathways that regulate myriads of cellular functions and is
therefore highly regulated. In fact GSK3β is regulated at multiple levels. GSK3β recognizes
substrates that have been previously primed by other kinases. This adds to the selectivity of
kinase activity of GSK3β toward a substrate. Usually, GSK3β recognizes the motif “S/T-X-X-XS/TP” where the S/TP stands for the primed phosphorylated residue on the substrate [148].
However, GSK3β is capable of binding and phosphorylating both primed and unprimed substrates
in a context-dependent manner. The ability of GSK3β to bind unprimed substrates also make the
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phosphorylation status of the S9 residue irrelevant to its function in relation to that particular
substrate [148].

Another major regulatory mechanism is the post translational modifications of the enzyme itself.
GSK3β activity is regulated through phosphorylation by other kinases such as Akt, ERK, FYN,
p38MAPK, PKA, PYK2, and Src and by phosphatases such as PP1 and PP2A [77, 148].
Phosphorylation of GSK3β on Ser9 residue (Ser21 for GSK3α) inactivates the kinase whereas
the phosphorylation of Tyr216 within the activation loop, increases its kinase activity [149, 150].
However, this regulation by phosphorylation is not as simple or straight forward as it appears. The
phosphorylation status of GSK3β on the Ser9 residue is in a constant state of oscillation between
phosphorylated and unphosphorylated [148, 151]. The phosphorylated residue inhibits GSK3β
function by binding to the pocket to which primed substrates bind. Therefore, this inhibitory effect
also depends on the concentration of the primed substrate present [148]. When the concentration
of the primed substrate increases, it displaces the phosphorylated S9 residue and the enzyme is
rendered active again. Additionally, in order for the catalytic activity to take place both the major
domains, the β-strand domain and the α-helical domains, must align into a catalytically active
conformation to effectively bind appropriate substrates [148].

The substrate specificity and availability of GSK3β is also dictated by the association of the kinase
with different protein complexes. The association of GSK3β with the destruction complex is one
of the well-studied ones [148]. About 10% of the GSK3β present in the cells is found to be bound
to Axin. Axin, in the destruction complex, binds GSK3β, Casein Kinase 1 (CK1) and β-Catenin
and this facilitates the phosphorylation of β-Catenin by GSK3β [148]. However, β-Catenin is not
the only substrate that binds both Axin and GSK3β. Other substrates of GSK3β such as Smad3,
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tuberous sclerosis complex 1 (TSC1)/ hamartin and TSC2/tuberin have also been found to bind
to Axin and this binding facilitates their phosphorylation by GSK3β [148]. Other scaffolding
proteins with which GSK3β forms complexes include but are not limited to 14-3-3 proteins,
glycogen synthase kinase 3β interacting proteins (GSKIP), protein 4.1R and suppressor of fused
(sufu) [148].

In addition to the above-mentioned means of regulation, GSK3β is also regulated by subcellular
localization. GSK3β is present in 3 different pools, i.e. the mitochondrial pool, cytosolic pool, and
nuclear pool [148]. The mitochondrial GSK3β could play a role in the regulation of apoptosis. It
has been noted that during the induction of apoptosis, the active form of GSK3β is dramatically
upregulated in the mitochondria [148, 152, 153]. However, much is yet to be discovered about
the roles and regulation of mitochondrial pool of GSK3β. The nuclear pool of GSK3β is better
studied as a major proportion of GSK3β substrates are transcription factors. Some of the
transcription factors regulated by GSK3β include Fos/Jun, AP-1, CREB, heat shock factor 1,
nuclear factor of activated T cells (NFAT), myc, C/EBP, NFκB, p53, and signal transducer and
activator of transcription-3 (STAT3) [148, 154-156]. Interaction with FRAT protein facilitates
nuclear export of GSK3β [157]. Recently, roles in epigenetic alterations have also been attributed
to GSK3β.

Evidence indicates that GSK3β phosphorylates histones and promotes

phosphorylation of histones by other kinases [158, 159]. In addition, GSK3β also has been shown
to phosphorylate and either activate or inactivate HDACs and in turn HDACs alter the activity of
GSK3β [160-163].

Cytoplasmic pool of GSK3β is present in several compartments within the cytoplasm [148]. This
pool of GSK3β is in a constant flux shuttling between different compartments [164]. The well-
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studied portion of cytoplasmic GSK3β is the one that is found in the destruction complex. This
pool of GSK3β is often found to be compartmentalized in the endosomes [165]. It is important to
understand that this compartmentalization plays a very important role in contextual signaling of
GSK3β. For example, the endosomal compartmentalization of GSK3β associated with the
destruction complex allows GSK3β to signal both in Wnt-dependent and Wnt independent
pathways at the same time [165]. While facilitating the versatility of GSK3β, compartmentalization
also adds another layer of complexity while targeting GSK3β.

1E.

Role of GSK3β in cellular processes vital to metastasis

1E.a. Cell Cycle
Cell cycle is a highly regulated process by which the cells replicate. Cell cycle mainly is divided
into 4 phases – Gap1 (G1 phase), synthesis (S phase), gap 2 (G2 phase) and mitosis (M phase)
[166]. This complex cycle is regulated by cyclins and cyclin dependent kinases (CDKs) which
function together as complexes [166]. The CDKs are inactive kinases untill they form complexes
with the appropriate cyclins and this complex can then bind and phosphorylate the substrates.
The CDKs are ubiquitous but the levels of cyclins change dramatically depending on the phase
of the cell cycle [166]. Thus the cyclins follow a predictable pattern of expression and degradation
and this serves to regulate the cell cycle. For example, cyclin D is upregulated in the G1 phase
and binds to CDK4/6 whereas cyclin E is upregulated later in the G1 phase and binds to CDK2
and facilitates the transition from G1 to S phase [166]. There are several cyclins and several
CDKs, and the binding partners are yet to be determined. However, of all the cyclins, cyclin D1 is
highly altered in cancer [166, 167]. Cyclin D1 mRNA and protein levels are upregulated following
a mitogenic signal and remains high untill the mitogenic signal persists. Cyclin D1 interacts with
CDK4/6 to form a complex which is phosphorylated and activated by CDK activating kinase (CAK)
[168] . The activated cyclin D1/CDK4/6 complex then acts as a sequestering protein to prevent
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the interaction of CDK-inhibitory proteins from the cyclin E/CDK2 complex thus resulting in the
accumulation of this complex. Cyclin E/CDK2 phosphorylates and inactivates Rb protein which
acts as a gatekeeper protein by inhibiting its substrate E2F from transcribing its target gene such
as cyclin E which is required for progressing to the next cell cycle phase [166]. When the cell
enters the S phase, cyclin D1 is exported from the nucleus and is ubiquitinated and degraded by
26S proteasome [166]. It is in regulating the degradation of cyclin D1 that GSK3β plays a vital
role. Cyclin D1 is phosphorylated on threonine 286 by GSK3β [166]. This phosphorylation leads
its interaction with CRM1 which facilitates the export of cyclin D1 to the cytoplasm for subsequent
ubiquitination by SCF E3 ligase family and degradation [166]. Thus GSK3β is essential for the
turnover of cyclin D1 which is necessary for the progression of the cell cycle.

1E.b. Apoptosis
Apoptosis or programmed cell death is a well-orchestrated process by which a cell undergoes
self-destruction through a cascade of events. GSK3β has been demonstrated to play a very
important role in the regulation of apoptosis [169]. GSK3β has been attributed with the induction
of apoptosis following DNA damage, hypoxia and endoplasmic reticulum stress. It mainly brings
about this effect by phosphorylating and inhibiting pro-survival proteins such as CREB, heat shock
factor 1 and p53 [154, 169]. GSK3β phosphorylates the C-terminus of p53 at Ser-33 and facilitates
its pro-apoptotic function [170, 171]. p53 is a short lived protein and phosphorylation by GSK3β
facilitates other post-translational modifications that stabilize p53 [169]. GSK3β also promotes the
transcription of p53 target genes and regulates its subcellular localization. Binding of GSK3β to
p53 also alters GSK3β. In addition to this, GSK3β also phosphorylates and inhibits MDM3 which
is an E3 ubiquitin ligase responsible for ubiquitination and subsequent degradation of p53 [169,
172].
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GSK3β also regulates the intrinsic mitochondrial apoptotic pathway. The intrinsic apoptotic
pathway depends on the proportion of active anti-apoptotic Bcl-2, Bcl-XL, Bcl-w, Mcl1, and A1 and
pro-apoptotic proteins Bax and Bim belonging to the Bcl-2 family of protein [169, 173, 174]. Bax
sequesters the anti-apoptotic proteins and binds to the mitochondrial membrane that results in
the disruption of the mitochondrial membrane and the release of cytochrome c which in turn
triggers caspase cascade and apoptosis [169, 174, 175]. GSK3β is capable of phosphorylating
and activating Bax and phosphorylating Mcl1 and inhibiting its function [169]. Though, a proapoptotic function has been attributed to GSK3β, several studies have also highlighted the ability
of GSK3β to inhibit apoptosis. Thus, the ability of GSK3β to induce apoptosis depends on
substrate availability and its subcellular localization.

1E.c. Migration
Migratory potential of the cells is a major contributor to its metastatic potential. One of the means
by which EMT promotes metastasis is by enhancing the migratory properties of the cancer cells.
GSK3β has been reported to play a pivotal role in the migration of the cancer cells. There are
three major means by which GSK3β influences the migratory capacity of the cancer cells. These
mechanisms include regulation of the actin cytoskeleton dynamics, microtubule formation and the
interaction of the cells with their extracellular matrix (reviewed in [176]).
The actin cytoskeleton is mainly regulated by the Rho family of GTPases and of these Rac, which
influences lamellipodia formation, and Cdc42, which induces filopodia formation, are the most
studied members and control actin polymerization [176-178]. Rho is another member that is
equally well-studied but contributes to the cellular contractility. The Rho family proteins are highly
regulated by GTPases activating proteins (GAP) and p190 RhoGAP is one such protein that is
capable of regulating the activity of Rho family members and is in turn regulated by several
kinases including GSK3β [176, 179-181]. In p190A RhoGAP knockout fibroblasts, the actin
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polymerization was highly dysregulated and this could be corrected by overexpressing wild-type
p190A RhoGAP in these cells [176, 181]. However, the introduction of mutant p190A RhoGAP
that lacked the phosphorylation site for GSK3β was not capable of restoring the actin
polymerization to normalcy in the p190A RhoGAP -/- cells, indicating the importance of GSK3β in
the actin polymerization process [176, 181]. Thus, GSK3β can regulate cell migration by activating
Rho. It is important to note that p190A RhoGAP and not p190B RhoGAP is phosphorylated by
GSK3β and therefore GSK3β only influences the Rho proteins regulated by p190A RhoGAP and
not those influenced by p190B RhoGAP [176, 181]. GSK3β has also been reported to activate
ADP-ribosylation factor 6 (Arf6) which plays crucial role in vesicle trafficking, membrane ruffling
and lamellipodia formation [176, 182, 183]. GSK3β also activates Rac in several different cell
models and enables the cells to migrate. Thus GSK3β positively regulated cell migration by
exerting its influence on different factors controlling actin polymerization.

While actin polymerization provides the force for the cellular migration, the microtubules influence
the directionality of the movement. GSK3β has been reported to regulate several of the proteins
that are involved in the microtubule dynamics such as microtubule motor protein, proteins in the
microtubule organizing center (MTOC) and protein complexes at the plus ends of the microtubules
[176, 184]. The microtubules also serve to deliver different proteins from one part of the cell to
the other. Kinesins are proteins that are made of 2 heavy chains that bind the microtubule provide
a motor functionality to the protein and 2 light chains that can bind to the proteins such as APC
and focal adhesion dissociation factors [185, 186]. GSK3β is known to phosphorylate the kinesin
light chain and facilitate the dissociation of the protein bound to the light chain at its destination
site [176, 185]. This function of GSK3β plays a very important role in facilitating the cellular
migration and dissociation of focal adhesion complexes.
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A migrating cell is in constant contact with its extracellular matrix. These interactions serve to
determine the direction of the movement and also serve as temporary anchors to facilitate the
forward movement. Cell movement takes place by dissolution of the existing focal adhesion and
formation of the new focal adhesion. Paxillin is a component of the focal adhesion complex that
is regulated by several kinases such focal adhesion kinase (FAK), Src and GSK3β [187, 188].
Phosphorylation of paxillin by GSK3β allows for the formation and maturation of the focal
adhesions [176, 189]. Thus GSK3β regulates both dissolution and formation of focal adhesions
to facilitate cell motility and this is of note as the subcellular localization of GSK3β and the
availability of the substrate dictates whether GSK3β functions to dissolve or form focal adhesions.

In summary, GSK3β functions in diverse manners to facilitate the progression of cell cycle,
promotes apoptosis and facilitates cellular migration. Thus the effect of inhibition of GSK3β is
dependent on the cumulative effect of GSK3β on all the different cellular processes. Inhibition of
GSK3β might stall the cell cycle and thereby decrease the proliferation of the cells while inhibiting
apoptosis which is essential for inhibiting tumor progression. In addition to these effects inhibition
of GSK3β is also going to inhibit the migratory potential of the cancer cell. Thus the effect of
GSK3β inhibitor on a cancer depends on the cell type, the pool of GSK3β affected, the substrates
available and the cellular processes predominantly affected. This proves that the role of GSK3β
as a tumor promoter or suppressor is entirely context dependent. The most important observation
from these studies is that GSK3β plays context dependent role in cancer and this is mediated
both in a Wnt signaling dependent and Wnt signaling independent manner and as GSK3β plays
different roles in different cancers, it is essential to understand the role of GSK3β in breast cancer.
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1E.d. Contribution of GSK3β to breast cancer.
Several studies have been conducted to delineate the role of GSK3β in breast cancer. GSK3β
has multiple targets and regulates several key players in breast cancer progression. In breast
cancer, hyperactivation of Wnt/β-catenin pathway is implicated as discussed above and GSK3β
is a negative regulator of the Wnt signaling pathway. However, no mutations in GSK3β have been
reported in breast cancers [190]. GSK3β is also associated with the induction of apoptosis in
breast cancer. Exogenous overexpression of kinase dead GSK3β, which is presumed to function
as an inhibitor of endogenous GSK3β, was observed to promote breast cancer [191, 192]. In
MCF7 cell line, kinase dead GSK3β led to the emergence of chemoresistance to doxorubicin and
decreased its sensitivity to tamoxifen as compared to the MCF7 cells overexpressing the wildtype GSK3β [191, 193]. On the other hand, the same MCF7 cells overexpressing kinase dead
GSK3β, which displayed decreased sensitivity to doxorubicin and tamoxifen, exhibited increased
sensitivity to rapamycin as compared to the MCF7 cells overexpressing the wild type GSK3β [191,
193]. Overexpression of constitutively active GSK3β increased chemosensitivity and induced cell
cycle arrest both of which contributed to reduced tumorigenicity [191]. GSK3β inhibitor SB415286
was shown to induce EMT in MCF10A cells [194]. GSK3β is known to inactivate NFκB, which is
an activator of Snail, an EMT inducing transcription factor in epithelial cells [191, 194]. This study
demonstrated that GSK3β inhibitor SB415286 induced EMT by activating NFκB which in turn
activated Snail [191, 194]. GSK3β has also been shown to phosphorylate and regulate both Snail
and Slug, by marking them for degradation [195, 196].

While several studies indicate that GSK3β is a tumor suppressor in breast cancer, other studies
contradict these findings. Studies have shown that GSK3β overexpression, detected by
immunohistochemistry, correlates with poor prognosis [197]. Quintayo et.al, used the Edinburgh
Breast Conservation series to study the correlation between GSK3β and disease prognosis in
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these breast cancer patients [197]. The Edinburgh Breast Conservation Series consists of 1812
patient samples along with the complete history of their treatment and outcomes collected
between 1981 and 1998 [197]. Of these samples, only 1681 tissue blocks were available and
were included in this study [197]. These were sectioned to create a tissue microarray, which was
used for immunohistochemical staining for GSK3β, p-GSK3β as well as other markers, and the
stained tissues were histoscored [197]. The patient samples were classified into high or low
expressing tissues based on the median histoscores and their distant relapse-free survival was
plotted [197]. Of the 1681 samples, about 70% of the samples were stained successfully and the
analysis showed that the samples that had high staining of GSK3β had shorter distant relapsefree survival, whereas no such correlation was observed in the case of p-GSK3β [197]. The
increased expression of GSK3β also correlated with the presence of metastatic lesions in the
lymph node [197]. Overexpression of GSK3β correlated with higher tumor grade and tumor size.
These tumors also lacked ERα, PR, and were characterized by an increased proliferative potential
[197].

Small molecule studies have also highlighted the fact that GSK3β inhibitors can serve as
therapeutic agents in breast cancer to overcome chemoresistance [198]. While GSK3β has been
attributed with tumor suppressive qualities [199], experiments have demonstrated that inhibition
of GSK3β is correlated with positive outcome in breast cancer. Clinical trials conducted with Eli
Lily GSK3β inhibitor, LY2090314, have demonstrated that GSK3β inhibitors improved the efficacy
of platinum drugs and the patients in whom stable disease was observed following treatment with
LY2090314 included a breast cancer patient [200]. Therefore, GSK3β inhibitors could serve as
novel therapeutic agents to treat breast cancers, either as a single agent or in combination with
standard of care drugs to help overcome chemoresistance or prevent the relapse of the disease.
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1F.

GSK3β, EMT and cancer stem cells.

GSK3β is a ubiquitous kinase regulating multiple signaling pathways and also playing an
important role in EMT. While GSK3β was first discovered for its role in regulating metabolism, it
gained much of its prominence as a key player in the Wnt/β-Catenin Signaling. Wnt is a wellknown promoter of stem cell properties and therefore GSK3β, an inhibitor of the Wnt signaling
pathway is commonly recognized as an inhibitor of stem cell properties. However, GSK3β is a
highly regulated kinase and therefore its role and function is dictated by the context in which it is
studied. GSK3β influences EMT by regulating the key players of EMT such as Snail, Slug and βCatenin.

GSK3β binds to and phosphorylates Snail [195]. The phosphorylation of Snail by GSK3β at a
single site marks it for ubiquitination by β-Trcp and thereby for destruction [195]. Phosphorylation
of a second site on Snail regulates its subcellular localization and results in the translocation of
Snail from the nucleus to the cytoplasm [195]. Inhibition of GSK3β was observed to upregulate
the expression of Snail and thereby inhibit the expression of E-cadherin, one of the most
prominent marker of epithelial phenotype [195]. GSK3β has also been shown to inhibit the
function of NFκB, which is an activator of Snail in MCF10A cells and this is the mechanism
proposed by which GSK3β helps epithelial cells to retain the epithelial phenotype [194]. Like Snail,
Slug is known to bind and inhibit the expression of E-cadherin. Phosphorylation of Slug by GSK3β
marks it for ubiquitination and subsequent degradation by carboxyl terminus of Hsc70-interacting
protein (CHIP) [196].
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In summary, GSK3β functions in diverse manners to facilitate the progression of cell cycle,
promotes apoptosis and facilitates cellular migration. Thus, the effect of inhibition of GSK3β is
dependent on the cumulative effect of GSK3β on all the different cellular processes. Inhibition of
GSK3β might stall the cell cycle and thereby decrease the proliferation of the cells while inhibiting
apoptosis which is essential for inhibiting tumor progression. In addition to these effects inhibition
of GSK3β is also going to inhibit the migratory potential of the cancer cell. Thus, the effect of
GSK3β inhibitor on a cancer depends on the cell type, the pool of GSK3β affected, the substrates
available and the cellular processes predominantly affected. This proves that the role of GSK3β
as a tumor promoter or suppressor is entirely context dependent.
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Chapter 2 – Statement of objective
2A.

Knowledge gap

TNBCs are highly metastatic tumors that are characterized by the presence of cells that have
undergone EMT and are enriched for cancer stem cells. As a result, there is higher risk of
developing chemoresistance, tumor relapse and metastasis that often prove to be fatal. The
mainstay of treatment for TNBCs is chemotherapy as they lack targeted therapy. Only about 30%
of the tumors respond to the chemotherapy and even these eventually tend to relapse and gain
chemoresistance [201]. The chemotherapeutic agents mainly function by killing the rapidly
proliferating cells in the tumors. However, TNBCs are enriched with CSCs and these cells are
unaffected by the standard of care chemotherapeutic agents. Therefore it is imperative to develop
novel targeted therapies to treat these aggressive cancers. The Wnt signaling pathway is one of
the most aberrantly activated pathways in TNBCs. This pathway has also been shown to play
pivotal role in the generation and sustenance of CSCs. GSK3β is a central player in the Wnt
signaling cascade, capable of independently regulating stemness [202]. Our goal was therefore
to examine the role of GSK3β in promoting EMT/CSC properties driving TNBCs & identify
potential druggable targets. Based on our preliminary findings in CSC-enriched TNBC cells, as
well as patient survival data analyzed from publicly available databases, we formulated the
following hypothesis.

2B.

Hypothesis

GSK3β inhibition can impede epithelial-mesenchymal-transition (EMT) and cancer stem
cell (CSC) properties and will serve as a novel drug target for EMT/CSC-enriched triplenegative breast cancers (TNBCs).
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2C.

Study questions – Aims

Aim 1 - Determine if GSK3β is upregulated in breast cancer and if this upregulation has clinical
significance.
Aim 2 - Investigate the relationship between GSK3β and Epithelial-Mesenchymal-Transition
(EMT) and cancer stem cell (CSCs) properties.
Aim 3 - Test if GSK3β inhibitors can be effectively used in vivo to target CSC-enriched breast
cancer.

36

2D.
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Figure 3 – Schematic depiction of the study

Aim 1 - Determine if GSK3β is upregulated in breast cancer and if this upregulation has clinical
significance.
Q. Is GSK3β upregulated in breast cancer?
Approach
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Publicly available datasets (Ma [203], Richardson 2 [204] and TCGA [205]) were examined to
determine if GSK3β expression is upregulated in breast cancer tissues compared to normal
mammary tissues.

Q. Does the level of expression of GSK3β correlate with patient survival?
Approach


Kaplan-Meier plots were generated using KMPlotter to identify the players of the Wnt signaling
molecule that are associated with poor survival of TNBC and basal-like breast cancer patients
[206].

Aim 2 - Investigate the relationship between GSK3β and Epithelial-Mesenchymal-Transition
(EMT) and cancer stem cell (CSCs) properties in TNBC cells.

Q. Can GSK3β inhibitors be used to downregulate EMT in TNBC cells?
Approaches


A high throughput screen was conducted to identify small molecule inhibitors capable of
inhibiting EMT in EMT/CSC-enriched MDA MB 231 reporter cells (Expressing EMTreporters).



Western blotting and qRT-PCR assays were employed to assess the protein and mRNA
expression of markers of the epithelial and mesenchymal phenotype of treated cells.



Wound-healing assay was used to assess the effect of GSK3β inhibition on the migratory
properties of cells with mesenchymal phenotype, which are typically characterized by the
presence of enhanced migratory potential.
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Q. What is the effect of GSK3β inhibitors on the CSC properties of mesenchymal-like cells?
Approaches


The mammosphere forming assay (surrogate assay for stemness) was utilized to examine
the effect of GSK3β inhibition (via small molecule inhibitor and shRNA) on the sphereforming ability. GSK3β knock out MEFs were also used to assess the effect of GSK3β on
the sphere forming potential of MEFs.



CD44/24 surface antigen profile (an indicator of the level of stemness and differentiation)
of the mesenchymal-like cells were examined by FACS to determine the effect of GSK3β
on the stemness of the mammary cell lines with mesenchymal and CSC properties.

Q. Do GSK3β inhibitors selectively inhibit mesenchymal-like cells as compared to their epithelial
counterparts?
Approaches


Cell lines representing normal breast cells (MCF10A), epithelial transformed cancer cells
(MCF7) and EMT/CSC enriched cancer cells (Sum159) were treated with the GSK3β
inhibitors and their sensitivity to the inhibitors were evaluated using the MTT assay.



Cell lines exhibiting epithelial phenotype and mesenchymal phenotype were treated with
the drugs selected from the small molecule screen to identify those capable of selectively
inhibiting cells with mesenchymal properties.



Cells having epithelial and mesenchymal attributes and expressing green and red
fluorescent markers respectively, were plated in equal proportions to be co-cultured. The
co-cultures were treated with the GSK3β inhibitors and the proportion of red and green
cells was assessed using flow cytometry.
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Aim 3 - Test if GSK3β inhibitor can be effectively used in vivo to target CSC-enriched breast
cancer.
Q. Does GSK3β inhibitor alter the tumorigenic and metastatic potential of breast cancer cells?
Approaches


Immortalized and experimentally transformed human mammary cell line (HMLER-Snail)
and a highly metastatic murine mammary (4T1) cell line were used in an orthotopic model
to assess the effect of GSK3β inhibitor on the tumor size and metastatic potential of these
cells.



Immunohistochemical analysis was performed on the tissues harvested from the animals
to determine if the drug was effective in inhibiting GSK3β and consequently EMT, in these
cells in vivo.
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Chapter 3 – Experimental Approaches
Cell lines
Immortalized human mammary epithelial cells (HMLE), HMLE cells transduced with EMT
transcription factor Snail (HMLE-Snail), and Twist (HMLE-Twist) and HMLE cells transformed with
Ras and overexpressing Snail transcription factor (HMLER-Snail) were grown in HMLE media,
made by mixing MEGM (Lonza) and DMEM/F12 50:50 (Corning) and bovine pituitary extract
(BPE) (Lonza), insulin (Sigma), hydrocortisone (Sigma), penicillin, and streptomycin (Gibco/Life
Technologies), were added to the media. EMT/CSC enriched basal-like cell line, Sum159 were
cultured in Ham’s F12 media (Corning) containing additional fetal bovine serum (FBS) (Sigma),
hydrocortisone, insulin and penicillin and streptomycin. Transformed breast cancer cell line with
epithelial phenotype, MCF7 cells were cultured in DMEM/F12 media containing 10% FBS and
penicillin and streptomycin. HEK293T cells were grown in DMEM (Corning) with 10% FBS and
penicillin and streptomycin and were used for transfections. TNBC representative MDA MB 231
reporter cells that were used for the small molecule screen were grown in DMEM media with 10%
Tet-approved FBS and penicillin and streptomycin. Highly metastatic murine breast cancer cells,
4T1 and mouse embryonic fibroblasts (MEF) derived from wild-type and GSK3β knockout mice
were grown in DMEM media with 10%FBS and penicillin and streptomycin. All the cell lines were
a generous gift from the Weinberg Lab (Whitehead Institute, MIT) and the MEFs were a gift from
the Sarbosov lab (MD Anderson Cancer Center).

Plasmids used
shRNA to GSK3β in pGIPZ, a lentiviral vector, was purchased from the MD Anderson shRNA
core, and was used to silence GSK3β in the three mesenchymal cell lines, HMLE-Snail, HMLETwist and Sum159. pMIG, a retroviral vector, was modified to express RFP and luciferase enzyme
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to generate pMIRL plasmid, which was then used to label HMLER-Snail and 4T1 cells which were
used for in vivo experimentation.

Transduction
Transduction is a process by which a foreign DNA is inserted into the genomic DNA of a cell via
a viral vector. The transduction procedure is well standardized in the lab and was performed as
described previously in [207-209]. HEK293T cells were used to produce the viral particles. The
HEK293T cells were plated to 20% confluence. The packaging vectors required for the
transduction vary depending on whether a retroviral or the lentiviral vector was used. In case of
retroviral vectors, pCMV-VSV-G and pUMVC are used as packaging vectors whereas for lentiviral
vectors, pCMV-VSV-G and pCMV-∆R8.2dpvr are used as packaging vectors. pCMV-VSV-G has
the gene encoding the envelope protein whereas the pUMVC produces MuLV gag and pol
required for the packaging of retrovirus and pCMV-∆R8.2dpvr encodes the gag and pol required
for the packaging of the lentiviral particles [210]. The retroviral or the lentiviral vector carrying the
gene of interest or the shRNA was mixed with the appropriate packaging vectors and added to
DMEM (without FBS) media. The transfection reagent Fugene was added to this mixture and the
tube was gently inverted couple times to thoroughly mix the plasmids and the transfection reagent.
This transfection mixture was incubated at room temperature for 15 min following which the
mixture was added to the HEK293T plates in a dropwise manner. The plate was swirled gently to
ensure that the transfection mix was uniformly distributed and the plates were incubated at 37°C
for 12-16 hrs in an incubator. After the incubation, the HEK293T media containing the transfection
mix was replaced with media made by mixing the HEK293T media and the media for the target
cell line in a 1:4 ratio. This media was harvested after 24hrs, filtered and added to the target cells.
This media contains the viral particles produced by the transfected HEK293T. This process was
repeated twice and then the target cells that were transduced were selected based on selection
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markers present in the viral vector. If the viral vector had a fluorescent marker, the cells are sorted
using a flowcytometer to select the successfully transfected cells. In case of antibiotic markers,
the transduced cells were replated in media containing the appropriate antibiotic. These
successfully transduced cells were used for further analysis.

Drugs
Lithium chloride (LiCl), one of the oldest known GSK3β inhibitor, was dissolved in DMSO to make
a stock concentration of 10M. Stock of 10mM BIO (Calbiochem) was made in DMSO and TWS119
(Cayman Chemicals) was diluted in DMSO to make a stock of 10mM and were used in varying
working concentrations as detailed in Chapter 6 and 7.

MTT assay
The MTT assays were performed according to the instructions provided in the assay insert to
evaluate the IC50 for each of the cell type for each of the drugs. The 96-plate format was used
for this assay. HMLE-Snail, HMLE-Twist and Sum159 cells were trypsinized and viable cells were
counted using trypan blue. 1000 viable cells in 100ul of media were plated in each of the wells.
The cells were allowed to attach and the following day, the cells were treated with a range of
concentrations for each of the drugs from 0.1uM to 100uM. The control wells were treated with
DMSO. Following the treatment, 20ul of the MTT reagent (CellTiter 96® AQueous One Solution Cell
Proliferation Assay from Promega) was added to each of the well and the treated cells were
incubated at 37C. The absorbance at 490 nm was measured and was normalized to the DMSO
treated cells. The viability of the cells treated with DMSO were arbitrarily treated as 100% and the
viability of the cells treated with the different concentration of the drugs were calculated based on
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this. The formula used for calculating the viability of the cells treated with the drugs is as follows
–
%Viability = Absorbance490 of treated cells/ Absorbance490 of DMSO treated cells * 100
Using this data, a dose response curve was generated. The X-axis was transformed to log values
and a non-linear regression analysis was performed using Graphpad Prism to calculate the IC50
for all the drugs used in this study.

Western blot
Immunoblot procedure is well established in the lab and was followed as described in [208,
211].The cells that were to be studied were plated in 10 cm dishes and the cells were treated.
Following treatment, the cells were trypsinized and collected into 1.5 ml Eppendorf tubes. The
cells were pelleted and the pellets were treated with 100ul of the protein extraction buffer. The
protein extraction buffer was prepared by adding kinase inhibitor (“Complete” from Roche) and
phosphatase inhibitor (“PhosphoStop” from Roche) to the RIPA buffer (Sigma). The cell pellets
were incubated with the protein extraction buffer for 30 min. after which the protein extracts were
spun down and the supernatant were transferred to a new Eppendorf tube and were stored at 20C. The concentrations were quantified using Bradford assay from Biorad. Bovine serum
albumin (BSA) was used to generate protein standards which were used to plot a standard curve
from which the concentration of the proteins was estimated. 50ug of proteins were aliquoted and
added to 6X gel loading buffer consisting of bromophenol blue, glycerol and SDS. The proteins
were further denatured by heating the protein and gel loading buffer mixture for 10 min at 90C.
The heat denatured proteins were spun down and were loaded on to a polyacrylamide gel. The
polyacrylamide gel was prepared by mixing acrylamide and bis-acrylamide, resolving or stacking
buffer, water. Ammonium persulfate (APS) and tetramethylethylenediamine (TEMED) were
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added to catalyze the polymerization. The gels were loaded with 50ug of proteins and the
electrophoresis was carried out with the running buffer. After running, the segregated proteins on
SDS-PAGE gels were transferred to nitrocellulose membranes. The membranes were blocked
with milk and the blocked membranes were probed with different antibodies, Actin (SC-1616-R,
Santa Cruz), GSK3β (Cell Signaling), FOXC2 (from collaborator Dr.Naoyuki Miura), Fibronectin
(610077, BD Biosciences) and β-catenin (610153, BD Biosciences). Following incubation with the
primary antibody, the membrane was incubated with the appropriate secondary antibody
conjugated with horse radish peroxidase. Chemiluminescence was used to detect the expression
of the proteins.

qRT-PCR
The RNA extraction, quantification, cDNA synthesis and qRT-PCR analysis was performed using
the lab standardized method previously described in [212].The cells to be analyzed were
harvested and lysed using Trizol (Life Technologies). Qiagen RNA extraction kit was used to
extract RNA from these cells. The extracted RNA was quantified using Nanodrop
(Thermoscientific). 1000ng of RNA was used for cDNA synthesis using cDNA synthesis kit
(Applied Biosystems). The cDNA generated was used for qRT-PCR analysis. 96 or 348 well
formats were used for this analysis and the Vii7 system from Applied Biosystems was used to
perform this analysis. SyBr green (Applied Biosystems) was used as the detection agent. The CT
(threshold cycle) values generated were used to calculate ∆CT by subtracting the CT value of the
housekeeping or control gene from the CT value of the gene of interest for the same sample. This
serves to normalize the CT values for each sample based on the expression of the ubiquitous
genes such as Actin or GAPDH. ∆∆CT was computed by subtracting the ∆CT of a gene in the
control sample from the ∆CT of the same gene in the experimental sample. ∆∆CT is used to
assess the fold change in the expression of genes by using the formula 2^∆∆CT including GSK3β,
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Fibronectin, Vimentin, E-cadherin and Snail. The fold changes that were calculated were graphed
using Graphpad Prism.

Mammosphere assay
The sphere assay was performed as described in [60].Cells were harvested by trypsinization and
counted using trypan blue to ensure that the only live cells are plated for the mammosphere assay.
1000 cells were plated into each well of the low attachment 96 well plate in 100 ul of the
mammosphere media. The mammosphere media is MEGM media with 1% methylcellulose
(Sigma). EGF (10ng/ml) (Sigma-Aldrich), FGF (20ng/ml) (BD Biosciences) and heparin (4ug/ml)
(Sigma) were added to aliquots before feeding the spheres. The spheres were allowed to grow
for 10 days after which the spheres with diameter greater that 100um were counted. For drug
treatment, the drug was added to the media every time the media was refreshed every 2 days.
For the pre-treatment assay, the cells were treated with GSK3β inhibitors for 24 hrs. Following
treatment, viable cells were counted using trypan blue and were plated for the mammosphere
assays. The mammosphere media was refreshed for every 2 days. After 10 days, the
mammospheres were counted.

FACS analysis
The expression of CD24/44 surface antigen was performed as previously detailed in [60].Cells to
be used for this analysis were harvested and counted using trypan blue. 5x105 cells were used
for this analysis. The cells to be analyzed were suspended in (fluorescence activated cell sorting)
FACS buffer (PBS with 2% FBS). CD24 conjugated with PE (BD Biosciences) and CD44
conjugated with APC (BD Biosciences) were incubated with the cells for 30 min. on ice. Following
the incubation, the cells were thoroughly washed with the FACS buffer which is 1% FBS in
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Phosphate Buffer Saline (PBS). The cells resuspended in the FACS buffer were analyzed using
BD Accuri. Unstained cells were used as negative control. FACS uses differences in the light
scattering ability of the cells to differentiate between different populations of the cells within a
single pool of cells. The composition of each type of cell is different and therefore scatters the
light projected on it in differently. Similarly, the fluorescently labeled cells scatter light depending
on the fluorophore present on the cell. FACS was used to analyze the expression of CD24 and
CD44 on the surface of the cells and the cell surface profile thus generated were compared
between the treated and the untreated cells.

Wound healing assay
The parameters for the wound healing assay was established and described in [208]. Cells were
plated on 6 well plates and on coverslips (for performing immunofluorescence studies) and
allowed to grow to confluence. Once the cells were confluent, a scratch was made using a pipette
tip. The loosened cells were washed away using PBS. The cells were then incubated with media
containing either DMSO or GSK3β inhibitors. The scratch was imaged for the time 0 using the
fluorescent microscope (Axio). The initial wound was measured and was used to determine the
percentage of wound closed. The closing of the wound was monitored. 9 hrs. after the treatment,
the unclosed wound was measured. The cells were treated with either DMSO or GSK3β inhibitor
and the scratch was imaged and quantified after 9 hrs. Following this the scratches were fixed for
immunofluorescence studies.

Immunofluorescence
The immunofluorescence studies were conducted as detailed in [208]. For immunofluorescence
studies, the cells were plated on coverslips. The cells were fixed with 2% paraformaldehyde (USB)
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and permeabilized with Tween20 (Fisher Bioreagents). These cells were blocked with albumin
overnight and exposed to primary antibody of interest for 3 hrs. Following this the cells were
washed with TBST thoroughly and then exposed to the appropriate secondary antibody which
was labeled with a fluorophore (Alexa Fluor from Life Technologies). The nuclei of the labeled
cells were stained with DAPI and this were then mounted and covered with a coverslip. The
labeled cells were then imaged using Axio microscope.

In vivo experiment to test the efficacy of TWS119
The in vivo studies were carried out based on the methodology described in [60]. HMLER-Snail
and 4T1 cells were labeled with pMIRL. Therefore, the cells were red and the red cells were sorted
using FACS to select the cells that have been successfully transduced. pMIRL also expressed
the luciferase gene and were used for in vivo experiments. 10 NOD/SCID mice were used for the
HMLER-Snail experiments. 1x106 labelled cells were injected orthotopically and the cells were
allowed to grow until palpable tumors formed (1 week). The mice were randomized into 2 groups;
one group was control and were treated with DMSO whereas the other group was treated with
TWS119 (30 mg/kg) intraperitoneally. Similarly, 1x104 labeled 4T1 cells were orthotopically
injected into 20 wild-type mice. These mice were randomized into 2 groups once the mice
developed palpable tumors (4 days). One group was treated with DMSO and the other group was
treated with TWS119. All the mice were imaged weekly to monitor the tumor progression. At the
end of the experiment, the mice were sacrificed and the tumors and the lungs were isolated, fixed
and embedded. The luminescence data were analyzed and plotted.

Immunohistochemistry
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Immunohistochemical (IHC) staining was performed on the tumor samples isolated from mice
following the procedure described in [213]. The tumor tissues were fixed with 10% formaldehyde
(formalin) for about 12-16 hrs after which they were stored in phosphate buffered saline (PBS)
and subsequently paraffin embedded. The paraffin embedded sections were cut to give 5μm thin
sections which were used for the staining procedure. Following deparaffinization and rehydration,
antigen retrieval was performed by heating the slide containing the tissue section with citrate
buffer (pH-6) in a microwave for 20 min. Endogenous peroxidase activity was quenched using 3%
hydrogen peroxide and the sections were blocked at room temperature with 5% BSA and 0.3%
Triton-X in PBS for one hour. Sections thus processed, were incubated with 1:100 dilution of
primary antibodies, overnight at 4°C. Following the removal of the primary antibodies, the slides
were treated with Biotinylated secondary antibodies (Vector labs) for one hour and incubated with
Vectastain ABC reagent for 30 min. Slides were treated with DAB substrate (Vector labs) for 10
min, dehydrated, counterstained with Hematoxyllin and were mounted and imaged. All slides were
stained simultaneously with the controls in an automated stainer (Dako AutoStainer Plus). The
Envision Dual Link-HRP (Dako) was used for detection and diaminobenzidine was used as
chromogen (Dako Envision Kit). Hematoxylin (Dako) was employed as counterstaining. Finally,
the slides were dehydrated and mounted with a cover slip and imaged.

Statistical Method
All the samples were assayed in triplicate. The in vitro experiments were repeated at least three
independent times except for the validation studies and the experiments using the 11 drugs
isolated from the small molecule screen which were repeated 2 times. The in vivo experiments
included at least 5 mice per group as mention in the “experimental approaches”. All the graphs
are represented as mean±s.e.m., and the p values (significance) were calculated using Student’s
unpaired two-tailed t-test.
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Chapter 4 – Aim 1 – Determine if GSK3β is upregulated in
breast cancer and if this upregulation has clinical
significance.
GSK3β is upregulated in breast cancer.

4A.

It is very difficult to classify a kinase as a tumor suppressor or promoter as its role depends on
the context such as availability of substrates, localization and presence of other regulatory factors.
We analyzed several publicly available datasets and found that in the Ma dataset [203], the
Richardson 2 dataset [204] and the TCGA data set [205] in which there is a significant
overexpression of GSK3β in breast cancer tissues compared to normal breast tissue [214, 215]
(Figure 4). We observed a significant upregulation of GSK3β in the Richardson data set and this
is of note because the Richardson data set mainly comprises of basal-like breast cancer samples.
Therefore, the upregulation of GSK3β is more marked in this dataset as compared to the other
datasets that consist of samples of all the different types of breast cancer.
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Figure 4 – GSK3β is significantly upregulated in breast cancer. GSK3β is significantly
upregulated at the transcript levels in cancer tissues as compared to normal tissues in the
Ma (202), Richardson 2 (203), and TCGA (204) datasets.
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4B.

Elevated expression of GSK3β correlates with worse overall survival among

TNBC patients.
Using KM plotter, we studied the significance of the high of GSK3β in breast cancer. KMplotter is
an online tool that allows us to query the effect of a gene of interest on the overall survival of
patients [216]. This tool pools all the available patient survival data from multiple databases and
probes all the data available for the gene queried and generates a KM plot where the patients are
classified as high or low-expressing based on the median gene expression in the dataset. KM
plots are survival curves generated to indicate the time to an event [217]. We found that the higher
expression of GSK3β corresponds to worse overall survival in breast cancer patients. The breast
cancer patients were classified on the basis of the intrinsic subtype and a similar correlation
between elevated expression of GSK3β and worse survival was observed in patients with Luminal
A breast cancer, luminal B breast cancer and basal breast cancer (Figure 5). The hazard ratio for
several major players in different sub-types of breast cancer were extracted and tabulated in
Table 1 and plotted using Circos plot (Figure 6). Of all the Wnt signaling molecules examined,
GSK3B and FZD2 had HR greater than 1 in all the 4 categories of breast cancers investigated
indicating that higher level of expression of these genes correlate with worse overall survival in
these patients. However, the correlation between the expression of FZD2 and the overall survival
in the breast cancer patients examined in this section was not significant (p>0.01) (Table 1).
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A

C

B

D

Figure 5 – Higher GSK3β expression correlates with worse overall breast cancer survival.
Kaplan Meier (Km) Plots for GSK3β in all breast cancer (A), luminal A (B), luminal B (C),
and basal-like breast cancers (D)..
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1 GSK3B
2 FZD5
3 FZD2
4 FZD1
5 LRP6
6 WIF1
7 APC
8 DKK1
9 CTNNB1
10 FZD3
11 DVL1
12 FZD8
13 LRP5
14 FZD4
15 AXIN1
16 GSK3A
17 WNT3
18 LEF1
19 DVL2
20 TCF7

All
HR
1.67 (1.49-1.88)
1.1 (0.98-1.23)
1.09 (0.97-1.22)
0.96 (0.86-1.08)
0.94 (0.84-1.06)
0.92 (0.82-1.03)
0.89 (0.79-1)
0.87 (0.78-0.98)
0.87 (0.77-0.97)
0.83 (0.74-0.93)
0.81 (0.72-0.91)
0.81 (0.72-0.91)
0.81 (0.72-0.91)
0.8 (0.71-0.89)
0.76 (0.67-0.85)
0.75 (0.67-0.84)
0.73 (0.65-0.82)
0.71 (0.64-0.8)
0.68 (0.6-0.76)
0.67 (0.59-0.75)

Luminal A
Luminal B
Basal
HR
P
HR
P
HR
P
0 1.35 (1.13-1.63)
0.0011 1.78 (1.44-2.19) 0.000000038 1.93 (1.48-2.53) 0.00000094
0.11 1.1 (0.92-1.32)
0.3038 1.03 (0.84-1.26)
0.77 0.74 (0.57-0.97)
0.027
0.16 1.13 (0.94-1.35)
0.2 1.3 (1.06-1.6)
0.011 1.09 (0.84-1.41)
0.5363
0.51 0.86 (0.72-1.03)
0.107 1.09 (0.89-1.34)
0.39 1.08 (0.84-1.4)
0.5487
0.32 0.84 (0.7-1.01)
0.0632 1.12 (0.91-1.37)
0.27 0.88 (0.68-1.14)
0.3277
0.16 0.84 (0.7-1.01)
0.0663 0.95 (0.78-1.17)
0.6399 0.72 (0.55-0.94)
0.0139
0.046 0.8 (0.67-0.96)
0.018 0.97 (0.79-1.18)
0.75 1.22 (0.94-1.59)
0.127
0.0182 0.73 (0.61-0.88)
0.0007 0.88 (0.72-1.08)
0.24 0.7 (0.54-0.9)
0.0062
0.014 0.79 (0.66-0.94)
0.0099 0.85 (0.69-1.04)
0.1104 1.21 (0.93-1.57)
0.1564
0.0015 0.83 (0.69-0.99)
0.041 0.84 (0.68-1.03)
0.087 0.8 (0.61-1.03)
0.0856
0.00042 0.76 (0.64-0.92)
0.0036 0.91 (0.74-1.11)
0.3621 0.88 (0.68-1.14)
0.3406
0.00034 0.86 (0.72-1.03)
0.11 0.75 (0.61-0.91)
0.0047 0.86 (0.66-1.11)
0.2494
0.00038 0.71 (0.59-0.86)
0.00027 0.85 (0.69-1.04)
0.12 0.8 (0.62-1.04)
0.096
0.00011 0.69 (0.57-0.83)
0.000061 0.91 (0.75-1.12)
0.38 0.88 (0.68-1.14)
0.34
2.10E-06 0.79 (0.65-0.94)
0.0089 0.71 (0.58-0.87)
0.00081 0.74 (0.57-0.96)
0.0216
8.10E-07 0.68 (0.57-0.82)
0.000038 0.78 (0.63-0.95)
0.015 0.74 (0.57-0.96)
0.0222
8.80E-08 0.78 (0.65-0.94)
0.0074 0.94 (0.77-1.1)
0.58 1.12 (0.87-1.46)
0.3756
9.10E-09 0.8 (0.67-0.96)
0.018 0.76 (0.62-0.93)
0.0073 0.73 (0.56-0.95)
0.017
4.80E-11 0.62 (0.52-0.75) 0.0000003 0.75 (0.61-0.92)
0.0053 0.66 (0.51-0.86)
0.0018
5.80E-12 0.75 (0.62-0.9)
0.0016 0.56 (0.46-0.69) 0.000000028 0.72 (0.55-0.93)
0.0119

P

Table 1 – List of the hazard ratios and p-value of the players of the Wnt signaling in breast

.
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Figure 6 – Circos plot of the hazard ratios of components of Wnt signaling pathway. The
hazard ratio (HR) from the Km Plots for all the components of the Wnt signaling pathways
were plotted using Circos. The green bar marks the upper limit of the HR, the purple bar
plots the lower limit of HR and the blue bars plot the average HR. The HRs indicate that
GSK3β has the highest HR among all the Wnt signaling pathway players in all the subtypes
of breast cancer.

Additionally, KM plots were also generated for breast cancers based on the clinical classifications
i.e. ER/PR+, HER2+ and TNBCs. The KM plots indicated that there was no significant correlation
between the level of GSK3β expression and the overall survival of the patients with ER/PR+ or
HER2+ breast cancers (Figure 7). In the case of ER/PR+ breast cancers the hazard ratio was 1.6
54

and the p-value was 0.08. In the case of HER2 + breast cancer patients, the hazard ratio was
0.81 and the p-value was 0.6. However, in the case of TNBCs, the hazard ratio for GSK3β was
2.22 and this value was higher than that for most of the other major players in the Wnt signaling
pathway and with a significant p-value of 0.0051 (Figure 7). Thus the correlation between the
overexpression of GSK3β and the worse overall survival was found to be significant only in the
patients with TNBC (Figure 7). Among the Wnt signaling pathway players tested, GSK3β was the
only molecule for which the correlation between the expression and survival was significant in
TNBCs (Figure 8).

Summary – Aim 1: Thus far, we examined multiple datasets to assess the level of expression of
GSK3β in tumor tissues in comparison with that in the normal breast tissues. We found that
GSK3β was highly upregulated in breast cancer tissues as compared to the normal breast tissues
in Ma dataset, Richardson 2 dataset and the TCGA. This indicated that the expression of GSK3β
is dysregulated in breast cancers. We then analyzed publicly available patient survival data using
KMPlotter to determine if there is a significant correlation between the expression of GSK3β and
other Wnt signaling molecules in TNBC and indeed observed a significant correlation between
elevated levels of GSK3β and worse overall survival among TNBC patients. Our results taken
together serve to establish the basis for testing GSK3β as a potential target for TNBCs.
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ER/PR+

HER2+

TNBC

Figure 7 – The upregulation of GSK3β significantly correlated with worse survival of
TNBCs. Kaplan Meier Plots were generated for ER/PR+, HER2+ and TNBC patients to
determine how GSK3β correlates with the survival of these patients. The upregulation of
GSK3β significantly correlated with worse survival only in TNBCs and no significant
correlation was observed in other types of breast cancer.

56

4

Hazard Ratio

3

2

WNT3 (p=0.71)
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TCF7 (p=0.082)
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Figure 8 – GSK3β is the only signaling molecule in the Wnt signaling pathway that has a
high hazard ratio and a significant p-value. Hazard ratios and the p-values for several of the
major players of the Wnt signaling pathway were generated and plotted for TNBC patients.
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Chapter 5 – Aim 2 – Investigate the relationship between
GSK3β and Epithelial-Mesenchymal Transition (EMT) and
cancer stem cells (CSCs) in TNBCs

5A.

Small molecule screen indicates that BIO is a potential candidate capable

of decreasing mesenchymal phenotype.
A small molecule screen was conducted using MDA MB 231 reporter cells [218] (Figure 9). The
reporter cells have a Zeb1 reporter and E-cadherin promoter reporter. The Zeb1 reporter consists
of the 3’ UTR of Zeb1 that is cloned downstream the gene coding for GFP. When the cells have
a mesenchymal phenotype, miR200 expression is low and it cannot bind to the 3’ UTR of Zeb1
and therefore the expression of GFP, which is cloned upstream the 3’UTR of Zeb1 gene, is not
inhibited and the cells are green in color. When EMT is inhibited, the cells upregulate the
expression of miR200 which can now bind to the 3’UTR of Zeb1 and inhibit the expression of
Zeb1 gene and the expression of GFP in the Zeb1 reporter. Hence the green coloration
associated with mesenchymal properties is lost. The reporter cells also have an E-cadherin
promoter reporter in which dsRed is cloned behind the E-cadherin promoter. Therefore, with the
acquisition of epithelial phenotype the cells express E-cadherin and as a result dsRed cloned
downstream the E-cadherin promoter is turned on and the cells become red. The reporter cells
also express doxycycline (dox)-inducible miR200 which was used as a positive control.
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Figure 9 – MDA MB 231 reporter cell line. The MDA MB 231 reporter cells generated by
Toneff et. al. (217) were used to screen the drugs for their ability to inhibit EMT. When EMT
is inhibited, miR200 is expressed and suppresses the expression of Zeb1, thereby
suppressing the expression of GFP. In the meanwhile, E-Cadherin expression is turned on
and therefore the RFP is turned on. Thus the cells in which EMT is inhibited lose the green
color and gain red fluorescence.

The MDA MB 231 reporter cells were plated in 384 wells and were treated with a library of small
molecule inhibitors listed in Table 2-14. The cells were treated with three different concentrations
(0.1μM, 1μM and 10μM) of each of drug in the library for 5 days, following which the plates were
scanned for the presence of red and green fluorescence. The ratio of red to green was calculated
for all the wells and 11 drugs that produced a ratio greater than 1.5 were selected (Table 15). The
short listed drugs consisted of kinase inhibitors and histone deacetylase (HDAC) inhibitors. It was
interesting to note that among all the compounds tested, BIO, a GSK3β inhibitor was one of the
candidates that were able to decrease Zeb1 promoter activity (green) and increase E-cadherin
promoter activity (red) in the reporter cells.
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Drugs used in the small molecule screen
1

FG-4592

45

Dovitinib (TKI-258, CHIR-258)

2

Panobinostat (LBH589)

46

Sunitinib Malate

3

Obatoclax Mesylate (GX15-070)

47

HA14-1

4

LAQ824 (Dacinostat)

48

U0126-EtOH

5

Varespladib (LY315920)

49

JNJ-38877605

6

Cabozantinib (XL184, BMS-907351)

50

SRT1720

7

Malotilate

51

17-AAG (Tanespimycin)

8

Barasertib (AZD1152-HQPA)

52

Capecitabine

9

PA-824

53

Cisplatin

10

JNJ-26854165 (Serdemetan)

54

Plinabulin (NPI-2358)

11

ENMD-2076

55

Raltitrexed

12

Nintedanib (BIBF 1120)

56

Ridaforolimus (Deforolimus, MK-8669)

13

Motesanib Diphosphate (AMG-706)

57

Temsirolimus (CCI-779, NSC 683864)

14

Nutlin-3

58

Belinostat (PXD101)

15

BTZ043 Racemate

59

GDC-0879

16

Foretinib (GSK1363089)

60

Odanacatib (MK-0822)

17

Everolimus (RAD001)

61

YM155 (Sepantronium Bromide)

18

Brivanib Alaninate (BMS-582664)

62

17-DMAG (Alvespimycin) HCl

19

Docetaxel

63

CEP-18770 (Delanzomib)

20

AT13387

64

CP-724714

21

WZ4002

65

Regorafenib (BAY 73-4506)

22

Danoprevir (ITMN-191)

66

CUDC-101

23

Afatinib (BIBW2992)

67

Erlotinib HCl (OSI-744)

24

NVP-AEW541

68

Trichostatin A (TSA)

25

AUY922 (NVP-AUY922)

69

NVP-ADW742

26

MLN8054

70

OSU-03012 (AR-12)

27

SGX-523

71

Palbociclib (PD-0332991) HCl

28

TW-37

72

Alisertib (MLN8237)

29

ADL5859 HCl

73

Ivacaftor (VX-770)

30

SNS-314 Mesylate

74

MK-8245

31

Lenvatinib (E7080)

75

WZ3146

32

MK-2866 (GTx-024)

76

WZ8040

33

BIBR 1532

77

TAK-700 (Orteronel)

34

BMS-536924

78

Lapatinib (GW-572016) Ditosylate

35

Sorafenib Tosylate

79

Y-27632 2HCl

36

PHA-665752

80

OSI-906 (Linsitinib)

37

Vatalanib (PTK787) 2HCl

81

Danusertib (PHA-739358)

38

GSK690693

82

XL147

39

BMS-754807

83

AT9283

40

Andarine

84

SNS-032 (BMS-387032)

41

S3I-201

85

Ganetespib (STA-9090)

42

ABT-751 (E7010)

86

CYC116

43

BIIB021

87

XAV-939

44

Aprepitant

88

Irinotecan

Table 2 – List of the drugs from the Sellekchem small molecule library that were tested in
with their commonly used acronyms in parenthesis.
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Tabie 2 continued…
89

Decitabine

133

Tivozanib (AV-951)

90

PFI-1 (PF-6405761)

134

Oxaliplatin

91

Amuvatinib (MP-470)

135

Enzalutamide (MDV3100)

92

Rufinamide

136

Avagacestat (BMS-708163)

93

Asenapine

137

Ki16425

94

Flupirtine maleate

138

Losartan Potassium (DuP 753)

95

Ki8751

139

Cefoselis Sulfate

96

Drospirenone

140

Meropenem

97

Pirarubicin

141

Tenofovir

98

Bafilomycin A1(Baf-A1)

142

Sildenafil Citrate

99

Nanchangmycin

143

PHA-680632

100

Dimesna

144

Nelarabine

101

Clofarabine

145

KU-0063794

102

Latrepirdine

146

Dienogest

103

Posaconazole

147

PD173074

104

Biperiden HCl

148

Costunolide

105

Ginkgolide B

149

GSK1059615

106

Epothilone B (EPO906, Patupilone)

150

Daptomycin

107

Ruxolitinib (INCB018424)

151

Mizoribine

108

Rocuronium Bromide

152

Tigecycline

109

Droxinostat

153

Tianeptine sodium

110

Aurora A Inhibitor I

154

Cilomilast

111

Dutasteride

155

Bleomycin Sulfate

112

OSI-930

156

2-Methoxyestradiol (2-MeOE2)

113

Vinblastine

157

Entecavir Hydrate

114

Prasugrel

158

WYE-354

115

Budesonide

159

Dexamethasone (DHAP)

116

Granisetron HCl

160

MGCD-265

117

BMS-707035

161

Doripenem Hydrate

118

Isotretinoin

162

Nafamostat Mesylate

119

Stavudine (d4T)

163

Trilostane

120

Ranolazine 2HCl

164

Varenicline Tartrate

121

Ispinesib (SB-715992)

165

Zibotentan (ZD4054)

122

PIK-75

166

Carboplatin

123

Dexrazoxane HCl (ICRF-187, ADR-529)

167

Agomelatine

124

JNJ-7706621

168

Nepafenac

125

Cinacalcet HCl

169

Adapalene

126

Epothilone A

170

Etodolac

127

TG100-115

171

Rigosertib (ON-01910)

128

Bafetinib (INNO-406)

172

Gestodene

129

Lopinavir

173

Pelitinib (EKB-569)

130

Tenofovir Disoproxil Fumarate

174

Bimatoprost

131

Rilmenidine

175

Elaiophylin

132

Tipifarnib

176

Atazanavir Sulfate
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177

VX-745

221

Doxercalciferol

178

GW501516

222

Oligomycin A

179

Iloperidone

223

PHA-793887

180

LY2228820

224

Pracinostat (SB939)

181

SAR245409 (XL765)

225

Vinorelbine

182

BIX 02189

226

DMXAA (Vadimezan)

183

MK-3207 HCl

227

Dapagliflozin

184

PHT-427

228

Pomalidomide

185

BS-181 HCl

229

Tie2 kinase inhibitor

186

Erteberel (LY500307)

230

Darunavir Ethanolate

187

Erythromycin

231

Enalaprilat Dihydrate

188

Thiazovivin

232

Calcifediol

189

GSK429286A

233

VX-222 (VCH-222, Lomibuvir)

190

MC1568

234

Naratriptan

191

Mycophenolate Mofetil

235

Natamycin

192

AT7519

236

LY2811376

193

R406 (free base)

237

Telaprevir (VX-950)

194

AM1241

238

Nebivolol

195

AT7867

239

PD318088

196

Fasudil (HA-1077) HCl

240

Candesartan

197

Cefoperazone

241

Triamcinolone Acetonide

198

Amphotericin B

242

Lubiprostone

199

AZD6482

243

TSU-68 (SU6668, Orantinib)

200

Pimasertib (AS-703026)

244

Zosuquidar (LY335979) 3HCl

201

HMN-214

245

PIK-93

202

Lactulose

246

CCT129202

203

MK-1775

247

Hesperadin

204

Org 27569

248

Saxagliptin

205

SB408124

249

Pimobendan

206

BMS-777607

250

Tazarotene

207

BIRB 796 (Doramapimod)

251

Apixaban

208

Silodosin

252

Allopurinol

209

Amprenavir

253

Amorolfine HCl

210

Marbofloxacin

254

Safinamide Mesylate

211

SB525334

255

Daclatasvir (BMS-790052)

212

AEE788 (NVP-AEE788)

256

Ponatinib (AP24534)

213

Cyclosporine

257

Tosedostat (CHR2797)

214

Quizartinib (AC220)

258

BIX 02188

215

CP-673451

259

EX 527 (Selisistat)

216

Febuxostat

260

AZD8055

217

VX-809 (Lumacaftor)

261

KU-60019

218

RO4929097

262

Semagacestat (LY450139)

219

Prilocaine

263

Allopurinol Sodium

220

Telbivudine

264

Flurbiprofen
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265

Ipratropium Bromide

309

Desonide

266

Adefovir Dipivoxil

310

Esomeprazole Magnesium

267

Quetiapine Fumarate

311

Verteporfin

268

Fenoprofen Calcium

312

Azithromycin

269

Potassium Iodide

313

Alibendol

270

Nefiracetam

314

Elvitegravir (GS-9137, JTK-303)

271

PCI-34051

315

Benidipine HCl

272

Epalrestat

316

Lornoxicam

273

Tiopronin

317

Mecarbinate

274

Cilazapril Monohydrate

318

Fenoldopam

275

Isepamicin

319

Temocapril

276

Betamethasone Dipropionate

320

Divalproex Sodium

277

Azathioprine

321

Gadodiamide

278

Cefditoren Pivoxil

322

Teniposide

279

Erdosteine

323

Albendazole Oxide

280

Talc

324

Irsogladine

281

Cyclocytidine HCl

325

Maraviroc

282

PF-573228

326

Ginkgolide A

283

Phentolamine Mesylate

327

Cytidine

284

Pamidronate

328

Atorvastatin Calcium

285

Trimebutine

329

Dexmedetomidine HCl

286

Almotriptan Malate

330

Rasagiline Mesylate

287

Meprednisone

331

Emtricitabine

288

Terbinafine

332

Oxybutynin

289

Chlorprothixene

333

Ranitidine

290

Pranlukast

334

Flubendazole

291

Vitamin B12

335

Nystatin (Fungicidin)

292

Methscopolamine

336

Raltegravir (MK-0518)

293

BMS-265246

337

Uridine

294

Cyproterone Acetate

338

Gimeracil

295

Balofloxacin

339

Moexipril HCl

296

Ivabradine HCl

340

Betaxolol

297

Ambrisentan

341

Naltrexone HCl

298

Betamethasone Valerate

342

Deferasirox

299

Rifabutin

343

Pitavastatin Calcium

300

Oxytetracycline (Terramycin)

344

Acadesine

301

Atracurium Besylate

345

Dapoxetine HCl

302

Fluvastatin Sodium

346

Rimantadine

303

Adenine HCl

347

Pramipexole 2HCl Monohydrate

304

Suplatast Tosylate

348

Fenticonazole Nitrate

305

Doxifluridine

349

Terazosin HCl

306

Lafutidine

350

Clevidipine Butyrate

307

Rivastigmine Tartrate

351

Detomidine HCl

308

Temocapril HCl

352

Imidapril HCl
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353

Cisatracurium Besylate

397

Licofelone

354

Atropine

398

Neratinib (HKI-272)

355

Dabigatran Etexilate

399

Tebipenem Pivoxil

356

Bazedoxifene Acetate

400

AG-14361

357

SB743921

401

Avasimibe

358

CYT997 (Lexibulin)

402

Raf265 derivative

359

PIK-293

403

Mubritinib (TAK 165)

360

Apatinib

404

CAL-101 (Idelalisib, GS-1101)

361

LY2157299

405

Palomid 529 (P529)

362

AR-42

406

(+)-Usniacin

363

Andrographolide

407

Bergenin

364

Dronedarone HCl

408

Dextrose

365

Roflumilast

409

LDE225 (NVP-LDE225,Erismodegib)

366

LY2608204

410

RAF265 (CHIR-265)

367

PD128907 HCl

411

LY2784544

368

BGJ398 (NVP-BGJ398)

412

AZD8931 (Sapitinib)

369

A-966492

413

BMS-794833

370

Vinflunine Tartrate

414

PP242

371

PF-3716556

415

PIK-294

372

Telatinib

416

Fesoterodine Fumarate

373

Abiraterone Acetate

417

3-Indolebutyric acid (IBA)

374

Asiatic Acid

418

Bilobalide

375

Conivaptan HCl

419

S- (+)-Rolipram

376

AZD8330

420

Sitafloxacin Hydrate

377

LY2886721

421

AZD1480

378

Rosuvastatin Calcium

422

MLN2238

379

AST-1306

423

GSK461364

380

SGI-1776 free base

424

NVP-BHG712

381

AZ 960

425

CYT387

382

UK 383367

426

VX-765

383

Esomeprazole Sodium

427

GW791343 HCl

384

BKM120 (NVP-BKM120, Buparlisib)

428

Aloe-emodin

385

Azomycin

429

Cinchonidine

386

Arbidol HCl

430

Bazedoxifene HCl

387

GSK1292263

431

CGS 21680 HCl

388

KW-2449

432

PF-4708671

389

Givinostat (ITF2357)

433

MLN9708

390

SB505124

434

R406

391

Aliskiren Hemifumarate

435

OSI-420

392

DAPT (GSI-IX)

436

SB590885

393

TAME

437

Eltrombopag

394

Volasertib (BI 6727)

438

Degrasyn (WP1130)

395

CX-4945 (Silmitasertib)

439

Laetrile

396

Baicalin

440

Cyclosporin A
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441

Dihydroartemisinin (DHA)

485

Gramine

442

Kaempferol

486

Methyl-Hesperidin

443

Naringin

487

Oridonin

444

Puerarin

488

Sclareol

445

Stigmasterol

489

Ursolic Acid

446

Ammonium Glycyrrhizinate

490

Evodiamine

447

Indirubin

491

Rheochrysidin

448

Sophocarpine

492

Paeoniflorin

449

Astragaloside A

493

Rotundine

450

Levosimendan

494

Hexestrol

451

Manidipine 2HCl

495

Quinine HCl Dihydrate

452

Enoxolone

496

Gynostemma Extract

453

L-(+)-Rhamnose Monohydrate

497

Morin Hydrate

454

Neohesperidin Dihydrochalcone (Nhdc)

498

Orotic acid (6-Carboxyuracil)

455

Quercetin Dihydrate

499

Sclareolide

456

Tanshinone I

500

Vanillylacetone

457

Biochanin A

501

Gastrodin

458

Lappaconite HBr

502

Salidroside

459

Curcumol

503

Geniposide

460

20-Hydroxyecdysone

504

Synephrine HCl

461

Forskolin

505

Itraconazole

462

Ozagrel

506

Roxithromycin

463

Ergosterol

507

Hyodeoxycholic acid (HDCA)

464

Magnolol

508

Myricetin

465

Neohesperidin

509

Oxymatrine

466

Rutaecarpine

510

Shikimic Acid

467

Tetrahydropapaverine HCl

511

5-hydroxytryptophan (5-HTP)

468

Dioscin

512

Hematoxylin

469

Naringin Dihydrochalcone

513

Dihydromyricetin

470

Cephalomannine

514

Genipin

471

Aloperine

515

Guanosine

472

Equol

516

Lincomycin HCl

473

D-Pantothenic acid

517

Scopolamine HBr

474

Glycyrrhizic Acid

518

Icariin

475

(+)-Matrine

519

Myricitrin

476

Oleanolic Acid

520

(-)-Parthenolide

477

Salinomycin

521

Silymarin

478

Troxerutin

522

Aloin

479

D-Mannitol

523

Hordenine

480

Sesamin

524

Sodium Danshensu

481

10-Deacetylbaccatin-III

525

Geniposidic acid

482

Apocynin

526

Inosine

483

Clindamycin HCl

527

Manidipine

484

Propafenone HCl

528

Vardenafil HCl Trihydrate
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529

Xylazine HCl

573

Ciclopirox

530

Ceftiofur HCl

574

Trospium chloride

531

Hydralazine HCl

575

Prednisolone Acetate

532

Pramiracetam

576

Lonidamine

533

MG-132

577

OSI-027

534

PF-05212384 (PKI-587)

578

BMS-378806

535

A66

579

PF-04929113 (SNX-5422)

536

WYE-125132 (WYE-132)

580

PF-3845

537

Trametinib (GSK1120212)

581

Ibrutinib (PCI-32765)

538

PF-2545920

582

BMY 7378

539

Nepicastat (SYN-117) HCl

583

KX2-391

540

Epinephrine Bitartrate

584

L-Ascorbyl 6-palmitate

541

Scopine

585

Tolterodine tartrate

542

Cloxacillin Sodium

586

Streptomycin sulfate

543

Clindamycin palmitate HCl

587

Ribitol

544

GSK256066

588

Fostamatinib (R788)

545

PNU-120596

589

NPS-2143

546

TAK-875

590

GSK2126458 (GSK458)

547

ICG-001

591

Dolutegravir (GSK1349572)

548

A922500

592

CHIR-124

549

R547

593

TG101209

550

GDC-0980 (RG7422)

594

GSK1838705A

551

L-Adrenaline

595

Ritodrine HCl

552

Tiotropium Bromide hydrate

596

Sulbactam sodium

553

Amoxicillin Sodium

597

Dimethyl Fumarate

554

Oseltamivir phosphate

598

Noradrenaline bitartrate monohydrate

555

AZD5438

599

LY2603618

556

GW3965 HCl

600

DCC-2036 (Rebastinib)

557

NU7441 (KU-57788)

601

5-hydroxymethyl Tolterodine (PNU 200577, 5-HMT, 5-HM)

558

WAY-100635 Maleate

602

A-674563

559

BRL-15572

603

KW-2478

560

WAY-600

604

Resminostat

561

RS-127445

605

LY2109761

562

Phenytoin sodium

606

Isoconazole nitrate

563

Scopine HCl

607

Cortisone acetate

564

Medroxyprogesterone acetate

608

Tolvaptan

565

Tioxolone

609

TAK-733

566

Omecamtiv mecarbil (CK-1827452)

610

Tubastatin A HCl

567

URB597

611

CCT128930

568

SNX-2112 (PF-04928473)

612

MK-0752

569

Clinofibrate

613

PF-00562271

570

Flavopiridol HCl

614

NVP-BSK805 2HCl

571

ADX-47273

615

XL335

572

CH5132799

616

YO-01027
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617

Geldanamycin

661

AMG-900

618

Dacomitinib (PF299804, PF299)

662

MK-8776 (SCH 900776)

619

MK-4827 (Niraparib)

663

AMG-458

620

Milciclib (PHA-848125)

664

TH-302

621

Alectinib (CH5424802)

665

Dovitinib (TKI-258) Dilactic Acid

622

MK-2461

666

GW842166X

623

AZD2014

667

INCB28060

624

Torcetrapib

668

HCV-796 (Nesbuvir)

625

CEP-33779

669

INK 128 (MLN0128)

626

Torin 2

670

OC000459

627

Torin 1

671

SAR131675

628

LY411575

672

ZM 336372

629

SB415286

673

TG101348 (SAR302503)

630

PF-04691502

674

Anacetrapib (MK-0859)

631

HER2-Inhibitor-1

675

CUDC-907

632

MK-2048

676

MK-5108 (VX-689)

633

Nocodazole

677

M344

634

TAK-285

678

Tofacitinib (CP-690550,Tasocitinib)

635

VU 0357121

679

AZD4547

636

Dabrafenib (GSK2118436)

680

Ciproxifan

637

CI994 (Tacedinaline)

681

Tideglusib

638

Clindamycin

682

BI-D1870

639

CP-91149

683

JTC-801

640

Crenolanib (CP-868596)

684

PAC-1

641

CCT137690

685

BGT226 (NVP-BGT226)

642

Tivantinib (ARQ 197)

686

Canagliflozin

643

3-Methyladenine

687

Dalcetrapib (JTT-705, RO4607381)

644

CPI-613

688

I-BET151 (GSK1210151A)

645

A-803467

689

Istradefylline

646

WP1066

690

Galeterone

647

GDC-0068

691

BYL719

648

TAE226 (NVP-TAE226)

692

ML133 HCl

649

ARN-509

693

Cathepsin Inhibitor 1

650

TAK-901

694

PH-797804

651

AZ 3146

695

GSK1070916

652

AZ 628

696

GW788388

653

Varlitinib

697

NVP-BVU972

654

Dinaciclib (SCH727965)

698

655

PF-5274857

699

GW4064

656

Laquinimod

700

Sotrastaurin

657

Lonafarnib

701

Sirtinol

658

MPEP

702

Tyrphostin AG 879

659

RG108

703

Desmethyl Erlotinib (CP-473420, OSI-774)

660

R428 (BGB324)

704

SB269970 HCl

SB705498
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705

BRL-54443

749

MK-801 (Dizocilpine)

706

CTEP (RO4956371)

750

U-104

707

GW5074

751

A-205804

708

VU 0361737

752

MLN0905

709

Lumiracoxib

753

Pirfenidone

710

GW9662

754

Mozavaptan

711

CHIR-99021 (CT99021) HCl

755

Pifithrin-α (PFTα)

712

Rivaroxaban

756

Deuterated Atazanivir-D3-2

713

Piceatannol

757

Vildagliptin (LAF-237)

714

Purmorphamine

758

Solifenacin succinate

715

Azilsartan Medoxomil

759

Diclofenac Diethylamine

716

BML-190

760

StemRegenin 1 (SR1)

717

VU 0364770

761

Alogliptin

718

Camostat Mesilate

762

PJ34

719

SB742457

763

Cobicistat (GS-9350)

720

PF-477736

764

Tempol

721

ML161

765

PF-4981517

722

Evacetrapib (LY2484595)

766

Pifithrin-μ

723

Telithromycin

767

Deuterated Atazanivir-D3-3

724

Fenoprofen calcium hydrate

768

Sitaxentan sodium

725

Cinepazide maleate

769

Bosentan Hydrate

726

Medetomidine HCl

770

Guanosine Hydrate

727

MRS 2578

771

Golvatinib (E7050)

728

ML130 (Nodinitib-1)

772

TG100713

729

Prucalopride

773

PF-562271

730

ZM 323881 HCl

774

CCG 50014

731

JNJ-7777120

775

WZ811

732

HC-030031

776

Icotinib

733

Apoptosis Activator 2

777

Carbazochrome sodium sulfonate (AC-17)

734

Zanamivir

778

Rimonabant

735

Linagliptin

779

Bepotastine Besilate

736

Azilsartan

780

Rupatadine Fumarate

737

Epinephrine HCl

781

Vanillin

738

SB271046

782

IEM 1754 dihydrobroMide

739

VUF 10166

783

T0070907

740

Acesulfame Potassium

784

GW441756

741

ZM 306416

785

S-Ruxolitinib (INCB018424)

742

Ki16198

786

Dapivirine (TMC120)

743

IOX2

787

Salubrinal

744

TAK-715

788

Clevudine

745

Zaltoprofen

789

PMSF

746

Bindarit

790

Fosaprepitant dimeglumine salt

747

Otilonium Bromide

791

Azelnidipine

748

Diclofenac Potassium

792

Caspofungin Acetate
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793

Dexmedetomidine

837

2-Thiouracil

794

Tylosin tartrate

838

Adrenalone HCl

795

Reboxetine mesylate

839

Sitagliptin phosphate monohydrate

796

Cyclamic acid

840

Avanafil

797

Aclidinium Bromide

841

Methazolamide

798

Valganciclovir HCl

842

Vitamin D3

799

Zinc Pyrithione

843

Vitamin A Acetate

800

Halobetasol Propionate

844

Voglibose

801

Lorcaserin HCl

845

Desvenlafaxine

802

Succinylcholine Chloride Dihydrate

846

Levodropropizine

803

Cyclizine 2HCl

847

Penfluridol

804

Etravirine (TMC125)

848

Moguisteine

805

Altrenogest

849

Azatadine dimaleate

806

Schisandrin B (Sch B)

850

Pentamidine

807

Ouabain

851

Sodium Picosulfate

808

Sennoside A

852

Olsalazine Sodium

809

Retapamulin

853

Escitalopram Oxalate

810

Ticagrelor

854

Lomerizine HCl

811

Ifenprodil Tartrate

855

Eprosartan Mesylate

812

Estradiol Benzoate

856

Triclabendazole

813

Tilmicosin

857

Deoxyarbutin

814

Bacitracin

858

Doxycycline Hyclate

815

Ulipristal

859

Sodium salicylate

816

Anagrelide HCl

860

Ticarcillin sodium

817

Betulinic acid

861

Mirabegron

818

Allylthiourea

862

Tolcapone

819

Vitamin D2

863

Nafcillin Sodium

820

Methyclothiazide

864

Guanidine HCl

821

Sulfacetamide Sodium

865

Levobetaxolol HCl

822

Difluprednate

866

Diminazene Aceturate

823

Dicloxacillin Sodium

867

Isovaleramide

824

Sodium Phenylbutyrate

868

Clorprenaline HCL

825

Azithromycin Dihydrate

869

Cyromazine

826

Indacaterol Maleate

870

Sertaconazole nitrate

827

Eletriptan HBr

871

Azlocillin sodium salt

828

Cabozantinib malate (XL184)

872

Hyoscyamine

829

Sennoside B

873

Homatropine Methylbromide

830

Doxapram HCl

874

Estradiol Cypionate

831

Sodium Nitroprusside

875

Sodium Nitrite

832

Spiramycin

876

Oxymetholone

833

Dexlansoprazole

877

Closantel Sodium

834

Desvenlafaxine Succinate

878

Pefloxacin Mesylate Dihydrate

835

Retinyl (Vitamin A) Palmitate

879

Eprazinone 2HCl

836

Amfenac Sodium Monohydrate

880

Teriflunomide
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Tabie 2 continued…
881 1-Hexadecanol

925 Penciclovir

882 Ethacridine lactate monohydrate

926 Dirithromycin

883 Erythritol

927 Sodium ascorbate

884 Luliconazole

928 Ebastine

885 Brimonidine Tartrate

929 Bromocriptine Mesylate

886 Colistimethate Sodium

930 R-(-)-Apomorphine HCl Hemihydrate

887 Noscapine HCl

931 Mepenzolate Bromide

888 Fosfomycin Tromethamine

932 Lithium Citrate

889 Picrotoxinin

933 Misoprostol

890 SC-514

934 Delphinidin Chloride

891 Tofacitinib (CP-690550) Citrate

935 Ataluren (PTC124)

892 Trometamol

936 Domiphen Bromide

893 Aminothiazole

937 Ribostamycin Sulfate

894 Fidaxomicin

938 Prucalopride Succinat

895 Vilazodone HCl

939 Efaproxiral Sodium

896 Benfotiamine

940 Calcium Gluceptate

897 Emetine

941 Ractopamine HCl

898 Pinacidil

942 Nomifensine Maleate

899 Bentiromide

943 Oxeladin Citrate

900 Procodazole

944 TTNPB (Arotinoid Acid)

901 SN-38

945 Cyanidin Chloride

902 Pimecrolimus

946 AP26113

903 Climbazole

947 Cyclandelate

904 Isosorbide

948 Valnemulin HCl

905 Bucladesine Sodium Salt

949 Bromfenac Sodium

906 Tamibarotene

950 Etofibrate

907 Anisotropine Methylbromide

951 Ceftazidime Pentahydrate

908 Mepiroxol

952 Thiostrepton

909 Carbenoxolone Sodium

953 Pyrilamine Maleate

910 Brucine

954 Oxiglutatione Disodium Salt

911 Nitarsone

955 JNK-IN-8

912 Quercetin 4'-glucoside

956 Petunidin Chloride

913 LY404039

957 PF-04880594

914 Mezlocillin Sodium

958 Cinchophen

915 Tenatoprazole

959 Liothyronine Sodium

916 Deoxycorticosterone acetate

960 Epinastine HCl

917 EUK 134

961 Nicaraven

918 Apomorphine HCl

962 Clinafoxacin HCl

919 Moxalactam Disodium

963 Tolmetin Sodium

920 Nicotine Ditartrate

964 Bekanamycin

921 Dichlorisone Acetate

965 Pasiniazid

922 Sodium 4-aminohippurate Hydrate

966 JZL184

923 Quercetin 3,4'-di-O-β-glucopyanoside

967 Peonidin Chloride

924 NXY-059

968 EPZ005687
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Tabie 2 continued…
969

MEK162 (ARRY-162, ARRY-438162)

1013 Birinapant

970

Stattic

1014 XL388

971

PD168393

1015 Oprozomib (ONX 0912)

972

LY2090314

1016 T0901317

973

IWP-2

1017 SANT-1

974

SCH772984

1018 (+)-JQ1

975

AMG-517

1019 XL888

976

PYR-41

1020 BMS-833923

977

AZD1080

1021 Ilomastat (GM6001, Galardin)

978

UNC1999

1022 ONX-0914 (PR-957)

979

AGI-5198

1023 GZD824

980

PP2

1024 CZC24832

981

IPI-145 (INK1197)

1025 XL019

982

AZD3514

1026 VX-661

983

FMK

1027 Cilengitide

984

IWR-1-endo

1028 KY02111

985

GDC-0032

1029 NLG919

986

AZD3839

1030 SC144

987

P22077

1031 CFTRinh-172

988

VER 155008

1032 LY2835219

989

SSR128129E

1033 AVL-292

990

I-BET-762

1034 RKI-1447

991

GDC-0152

1035 GDC-0834

992

AZD2461

1036 Wnt-C59 (C59)

993

BAY 1000394

1037 PP1

994

EMD 1214063

1038 SGC 0946

995

GSK2334470

1039 PD123319

996

BAM7

1040 Zebularine

997

3-Deazaneplanocin A (DZNeP)

1041 KPT-185

998

IU1

1042 TCID

999

Batimastat (BB-94)

1043 OTSSP167

1000 LY900009

1044 PF-543

1001 GSK2190915 (AM803)

1045 (Z)-Pugnac

1002 SGI-110

1046 Z-VAD-FMK

1003 EPZ004777 HCl

1047 Epoxomicin

1004 BMN 673

1048 EPZ5676

1005 GSK J4 HCl

1049 LDK378

1006 GSK923295

1050 (-)-Blebbistatin

1007 AZD3463

1051 NU6027

1008 MLN2480

1052 EPZ-6438

1009 LDN-57444

1053 BMS-911543

1010 Marimastat

1054 Mdivi-1

1011 LY3039478

1055 BAF312 (Siponimod)

1012 PF-04620110

1056 GlcNAcstatin
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Tabie 2 continued…
1057 BIO

1101 AZD2858

1058 Bromosporine

1102 CO-1686 (AVL-301)

1059 SGI-1027

1103 AZ191

1060 Rilpivirine

1104 RGD (Arg-Gly-Asp) Peptides

1061 Rocilinostat (ACY-1215)

1105 Vortioxetine (Lu AA21004) HBr

1062 CEP-32496

1106 UPF 1069

1063 PRT062607 (P505-15, BIIB057) HCl

1107 Macitentan

1064 Dynasore

1108 Gefitinib (ZD1839)

1065 NSC 405020

1109 RG2833 (RGFP109)

1066 UNC1215

1110 OAC1

1067 Nexturastat A

1111 AZD1981

1068 DBeQ

1112 TAK-632

1069 Erastin

1113 JSH-23

1070 Suvorexant (MK-4305)

1114 AG-18

1071 EHop-016

1115 Empagliflozin (BI 10773)

1072 GSK2636771

1116 GDC-0349

1073 TAK-438

1117 Lomeguatrib

1074 Apremilast (CC-10004)

1118 Vorinostat (SAHA, MK0683)

1075 ABT-199 (GDC-0199)

1119 OTX015

1076 PluriSIn #1 (NSC 14613)

1120 RepSox

1077 C646

1121 MM-102

1078 ZM 39923 HCl

1122 ZCL278

1079 CNX-2006

1123 EPZ004777

1080 Ferrostatin-1 (Fer-1)

1124 PRX-08066 Maleic acid

1081 Edoxaban

1125 Tariquidar

1082 Tasisulam

1126 Scriptaid

1083 BIX 01294

1127 Pacritinib (SB1518)

1084 AZD5363

1128 AG-490 (Tyrphostin B42)

1085 VU 0364439

1129 UNC669

1086 Tubastatin A

1130 RGFP966

1087 Bardoxolone Methyl

1131 Golgicide A

1088 OG-L002

1132 RVX-208

1089 SMI-4a

1133 Tenovin-1

1090 Thiamet G

1134 GW9508

1091 KPT-276

1135 NSC 23766

1092 JIB-04

1136 BMS-345541

1093 IOWH032

1137 P276-00

1094 VE-821

1138 WHI-P154

1095 GW0742

1139 ME0328

1096 Butein
1097 ETP-46464
1098 Dasatinib
1099 SGC-CBP30
1100 Skepinone-L

Table 2 – List of the drugs from the Sellekchem small molecule library that were tested in
with their commonly used acronyms in parenthesis.
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Drug

Target

1

TSU-68 (Orantinib)

VEGFR, PDGFR, FGFR

2

Rocilinostat (ACY-1215)

HDAC

3

Trichostatin A (TSA)

HDAC

4

CUDC-101

HDAC, HER2, EGFR

5

PD168393

EGFR

6

SCH79797

Par1 antagonist

7

CP-673451

PDGFR

8

Panobinostat (LBH589)

HDAC

9

BIO

GSK3

10

Cabozantinib malate

VEGFR, Axl

11

GW9662

PPAR

Table 3 – List of the drugs that were most effective in inhibiting EMT in the mesenchymal
MDA MB 231 reporter cells and their reported targets.

All the 11 drugs that were shortlisted in the screen were validated using flow cytometry (Table
15). The reporter cells were plated in 24-well plates. The reporter cells were treated with 3 different
concentrations of the drugs (0.1μM, 1μM and 10μM) for 5 days and following treatment the cells
were analyzed using flow cytometry. MDA MB 231 cells that did not express the reporters were
used to set the quartiles to define the red positivity and green positivity. All the treated cells were
sorted and the percentage of cells in each quartile was plotted (Figure 10). The cells that fall in
the first quartile denote the reporter cells that have gained red color but lost the green color
indicating that the expression of Zeb1 is turned off and the expression of E-cadherin is turned on.
These cells are denoted in blue in Figure 10. The cells that fall in the second quartile are the cells
that have both red and green fluorescence indicating that both Zeb1 and E-cadherin are turned
on. Red is used to represent these cells in Figure 10. The cells that fall in the third quartile are
cells that express green but not red fluorescence indicating that these cells have retained
mesenchymal properties following the treatment and therefore the expression of Zeb1 is not
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inhibited and the E-cadherin is not expressed. These cells are marked in green in the graphs in
Figure 10. The cells that fall in the fourth quartile lack the expression of both red and green
fluorescence and are cells that neither express Zeb1 nor E-cadherin. These cells are represented
in purple in Figure 10. The drugs that were able to increase the expression of E-cadherin and
consequently increase the proportion of the cells in the second quartile were selected. Among all
the drugs tested, GSK3β inhibitor, BIO and CUDC-101 were the only drugs that effectively
enabled the transition of the mesenchymal-like cells to red expressing reporter cells (Figure 10).
CUDC-101 is a multi-therapeutic drug that is capable of inhibiting HER2, EGFR and HDAC [219].
However, we were seeking to identify novel targets for treating TNBCs that lack the amplification
and overexpression of HER2. There are several studies examining the effect of HDAC inhibitors
on TNBCs [220-224]. Therefore, CUDC-101 did not appear to be a good candidate for this study.
As patient studies indicated that GSK3β could be a viable target to treat TNBCs that have been
observed to upregulate this kinase, BIO was selected for further studies.
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Figure 10 – CUDC1 and BIO are capable of inhibiting EMT. A. MDA MB 231 reporter cells
were treated with different doses of the drugs shortlisted from the screen for 5 days. These
cells were then analyzed using flowcytometry. Few of the drugs killed the cells and therefore
could not be analyzed. Among these drugs, only CUDC1 and BIO were capable of
decreasing the number of green positive cells while also upregulating the expression of
RFP. B. Heatmap of the ratio between red and green cells. Red indicated more epithelial
cells.
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BIO refers to 6-Bromoindirubin-3’-oxime which is a bromo derivative of indirubin [225]. Bis-indole
alkaloid indirubin and its analogs, collectively known as indirubins, were first discovered as
inhibitors of cyclin dependent kinases (CDKs) [225, 226]. Indigo and indirubin are isomers that
are derived from isatin and indoxyl via non-enzymatic dimerization [225]. The 2 components of
the indirubins are usually found free or conjugated with carbohydrates [225]. Indirubins can be
extracted from dye- producing plants, Muricidae mollusks and wild-type and recombinant bacteria
[226]. Interestingly, indirubin is an active ingredient in Danggui Longhui, a traditional Chinese
medicine recipe used to treat chronic myelocytic leukemia [225]. While it was discovered as a
CDK inhibitor, it was later determined that it could also inhibit GSK3β [225]. Recent studies have
indicated that chemical modifications to indirubins alter their affinity for kinases and thus 6Bromoindirubin-3’-oxime was found to have higher affinity for GSK3β as compared to other
kinases and methyl-derivative of BIO was found to be ineffective in binding to GSK3β [225].
Thus, this screen served to further attest that GSK3β may be an important player in TNBC and
that GSK3β inhibitors could serve as a potent therapeutic agent to revert EMT/CSC properties of
TNBC cells.

5B.

GSK3β inhibitors decrease the mesenchymal properties of the stem cell-

enriched mesenchymal-like cell lines.
The small molecule screen and the subsequent validation clearly demonstrated that the GSK3β
inhibitor, BIO is a potent inhibitor of EMT in TNBC cells. However, it was essential to test if this
phenomenon was limited to BIO or whether this is true for other GSK3β inhibitors too. To ensure
that our observations are robust we test 3 different GSK3β inhibitors that function via different
mechanisms on 3 different cell lines with mesenchymal properties. The 3 GSK3β inhibitors used
in this study include BIO, which was one of the lead candidates of the screen, LiCl, which has
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been in the clinic for treatment of neurological disorders for more than half a decade and TWS119,
a GSK3β inhibitor for which GSK3β is the only established target [202, 227].

After 50 years of using lithium for treating manic-depression (Bipolar disorder), GSK3β was
identified as one of its targets [227]. Lithium inhibits GSK3β via 2 different mechanisms [227]. It
competes with the magnesium ions for binding to the kinase [227]. Magnesium ions are essential
for the catalytic activity of kinases. The other mechanism of action of lithium is to increase the
inhibitory serine-9 (inactivating) phosphorylation of GSK3β [227-229]. This indirect effect has
been attributed to the effect of lithium on protein-phosphatase-1 or on the activated Akt [227, 230,
231]. Unlike most of the other GSK3β inhibitors, lithium does not inhibit CDKs [232]. Inhibition of
GSK3β using lithium chloride decreases the active form of GSK3β in all the 3 sub-cellular
compartments (cytoplasm, nucleus and mitochondria) in which GSK3β has been detected and
reported. As lithium has been in the clinic for a very long time, it has a known safety profile.
Notably, studies have shown that prolonged use of lithium doesn’t increase tumor incidence [233,
234].

TWS119 is a 4,6-disubstituted pyrrolopyrimidine. It was originally discovered in a screen used to
identify small molecules that were capable of inducing differentiation in P19 embryonic stem cells
(ESC) [202]. TWS119, which was identified in this screen was shown to bind to GSK3β via affinity
chromatography and this interaction was confirmed by western blotting and surface plasmon
resonance (SPR) [202]. Additionally, some of the studies mentioned TWS119 to be specific for
GSK3β inhibition [215].
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The 3 cell lines consistently used in these studies include HMLE-Snail cells, HMLE-Twist cells
and Sum159 cells. HMLE cells are human mammary epithelial cells that have been immortalized
and have an epithelial phenotype. The overexpression of EMT inducing transcription factors Snail
and Twist in the HMLE cells gives rise to the HMLE-Snail and HMLE-Twist cells respectively.
Therefore, HMLE-Snail and HMLE-Twist cells are epithelial cells that have been forced to undergo
EMT by the overexpression of EMT inducing transcription factors and thereby exhibit
mesenchymal properties and are enriched for stem-like cells. Sum159 cells are mesenchymallike cells that are enriched for CSCs. All the three cell lines were treated with BIO (1uM), LiCl
(20mM) and TWS119 (2uM) for 24hrs. These concentrations are close to IC25 calculated for
24hrs for these drugs for the cell lines used in this experiment. The lowest IC25 among the IC25s
of the 3 cell lines (HMLE-Snail, HMLE-Twist and Sum159) was finalized as the concentration for
treating all the cells). 0.5x10^6 cells were plated in a 10 cm dish and the cells were allowed to
attach overnight. The attached cells were treated with the appropriate concentration of the drugs
and the control cells were treated with DMSO (0.05%) for 24 hrs following which the cells were
harvested for protein and RNA extraction. The protein extraction was performed as described in
the “Experimental approaches” section and the proteins were quantified using the BioRad
Bradford Assay. 50ug of each protein sample was loaded onto the gel and the western blot
analysis was performed as described in Experimental approaches. The membrane was probed
for β-Catenin, FOXC2, Fibronectin and β-Actin. The β-Catenin levels were seen to increase
following treatment with GSK3β inhibitors, indicating that GSK3β is indeed inhibited leading to the
accumulation of β-Catenin in the treated cells. The expression of FOXC2 and fibronectin which
serve as indicators of mesenchymal phenotype was decreased (Figure 11).
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Figure 11 – GSK3β inhibitors decrease the expression of mesenchymal markers. FOXC2
and Fibronectin. HMLE-Snail, HMLE-Twist and Sum159 were treated with BIO, TWS119 or
LiCl for 24 hrs and levels of β-Catenin, Fibronectin, and FOXC2 were assessed by Western
Blot.

The RNA was extracted using the Qiagen RNA extraction kit and the RNA was quantified using
the Nanodrop from Thermoscientific. The cDNA generated using this RNA was used for qRTPCR and the levels of expression of mesenchymal and epithelial markers fibronectin, vimentin
and E-cadherin were tested for HMLE-Snail and HMLE-Twist cells and fibronectin, Snail and Ecadherin were tested for Sum159 cells. The expression of the housekeeping gene, GAPDH gene
was used for normalization. In line with the western blot analysis, we found a decrease in
expression of mesenchymal markers, fibronectin, vimentin and Snail and a significant increase in
the expression of epithelial marker, E-cadherin at the transcript level (figure 12).
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Figure 12 – GSK3β inhibitors decrease the expression of mesenchymal markers.
HMLE-Snail, HMLE-Twist and Sum159 were treated with BIO, TWS119 or LiCl for 24
hrs and RNA expression levels were assessed for FOXC2, Fibronectin, and Ecadherin by qRT-PCR.

In summary, the KM Plots demonstrated a correlation between the expressions of GSK3β and
overall patient survival in TNBCs and the small molecule screen confirmed that GSK3β indeed
could be a regulator of EMT, which is a major player in TNBC. The western blot analysis and qRTPCR analysis, demonstrated a decrease in the expression of mesenchymal markers and an
increase in the expression of epithelial markers following exposure to GSK3β inhibitors
suggesting that GSK3β could serve as a druggable target to inhibit EMT/CSC enriched TNBCs.

5C.

Inhibition of GSK3β decreases the migratory properties of the cells with

mesenchymal phenotype by inhibiting the induction of EMT.
EMT along with bestowing mesenchymal properties to the cells also enhances the migratory
potential of the cells. GSK3β inhibitors have been known to inhibit migration of cells [227, 235,
236]. Since our experiments demonstrated that GSK3β inhibitors inhibit the mesenchymal
properties of the cells, this led us to investigate if GSK3β inhibitors could inhibit the migratory
properties of the cells with mesenchymal properties. The wound healing assay was employed to
test the efficacy of the GSK3β inhibitors in inhibiting the migratory potential of the cells with
mesenchymal properties. HMLE-Snail cells, HMLE-Twist cells and 4T1 cells were plated for the
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scratch assay. 4T1 cells are highly metastatic murine mammary tumor cells [237, 238]. These
have been previously shown to have high migratory potential [237, 238]. All the cells were allowed
to grow to confluency and a scratch was made to mimic a wound as described in experimental
approaches. The control was treated with DMSO (0.05%) (vehicle) whereas the experimental
cells were treated with two GSK3β inhibitors, LiCl (20mM) and TWS119 (1uM). The scratch was
imaged at 0 hr and at regular intervals following treatment (Figure 13). Within 9hr following the
scratch, a significant difference was observed in the ability of the treated and the untreated cells
to close the wound. 3 images were acquired of each scratch at 0hr and at 9hr and the scratch
was measured in 3 different spots along the wound in each image. The measurements were
averaged to determine the distance between the wound edges. The percentage of the wound
closed was calculated as follows
% wound closed = (wound at 0hr - wound at 9hr) x 100
wound at 0hr

The % wound closed was plotted using GraphPad Prism. The images and the graphs clearly
demonstrate a significant decrease in the ability of the cells treated with GSK3β inhibitors to close
the wound as compared to that of the DMSO treated cells. This observation indicates that
exposure to GSK3β inhibitor significantly decreases the migratory potential of the cells with
mesenchymal properties (Figure 13).
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Figure 13 –GSK3β inhibitors significantly inhibit the ability of the highly migratory cells to
close the wound. A. HMLE-Snail, HMLE-Twist, and 4T1 cells were grown to confluency,
treated with LiCl or TWS119 and a scratch was made. After 9 hours closure of the scratch
was assesses. B. Quantification of the scratch assay.

This observation prompted the question of whether the EMT inhibition is one of the means by
which GSK3β inhibitors reduce the migratory potential of the cells with mesenchymal attributes.
In order to answer this question, a modification of the scratch assay was employed as previously
described in [208]. The cells used for the scratch assay were grown on coverslips and the scratch
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was made on the confluent layer of cells on the coverslip. A scratch assay was performed using
HMLE cells, which are epithelial cells and therefore do not express genes such as FOXC2 which
are exclusively expressed in cells that display mesenchymal phenotype [60, 89]. However, it has
been established that EMT is induced at the wound edge to facilitate the wound healing process
[111]. Therefore, when a scratch is made in HMLE cells grown to confluence, EMT is induced at
the wound edge to promote the closing of the wound. This has been tested in our lab previously
and when a scratch made in HMLE cells is stained for FOXC2 after 9hrs of having made the
scratch, FOXC2 expression was observed in the cells present at the wound edge indicating the
induction of EMT in these cells [208]. Using this as the basis for our experimental design, we
plated HMLE cells and allowed them to grow to confluence. A scratch was made in these cells
and the controls were treated with DMSO (0.02%) (vehicle) and the experimental cells were
treated with TWS119 (1uM). As expected, treatment with TWS119 decreased the ability of the
HMLE cells to close the wound as compared to the DMSO treated cells. These coverslips were
stained for the expression of FOXC2 and the nuclei were stained with DAPI. The DMSO-treated
scratch showed the upregulation of FOXC2 at wound edge but there was no upregulation of
FOXC2 at the wound edge in the scratch treated with TWS119 (Figure 14). This observation
indicates that GSK3β inhibitors decrease the migratory properties of the cells by inhibiting the
induction of EMT in the migrating cells.
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Figure 14 – Treatment with TWS119, inhibited the expression of FOXC2 at the wound site
of HMLE cells and thereby inhibits wound healing and migration. HMLE cells were grown to
confluency, treated with TWS119 and a scratch was made. After 9 hours expression levels
of FOXC2 (red) were assessed by immunofluorescence (207).

5D.

GSK3β inhibitors decrease the stem cell properties of mesenchymal-like

cells.
Cells that have undergone EMT along with exhibiting mesenchymal properties also possess more
stem-like properties [67]. It is well established in literature that EMT and CSC properties are
intricately linked. As GSK3β inhibitors were capable of inhibiting EMT, it was logical to investigate
if GSK3β inhibitors were capable of inhibiting the CSC properties of these mesenchymal-like cells.
The drugs that were shortlisted from the small molecule screen were tested for their ability to
inhibit the CSC properties of the MDA MB 231 reporter cells.

The MDA MB 231 reporter cells were counted and 1000 cells per well were plated in ultra-low
attachment plates in the visscous mammosphere media. The control wells were treated with
DMSO (0.05%) and the rest of the wells were appropriately treated with the 3 different
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concentrations of all the small molecule inhibitors that were indicated to be EMT inhibitors from
the screen. The media was replenished with the drugs every 2 days. At the end of 10 days the
number of mammospheres formed in each well were counted and plotted using GraphPad Prism
(Figure 15). BIO was found to be one of the drugs that were capable of inhibiting the sphere
forming capacity of these mesenchymal-like cells (Figure 15).
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Figure 15 – The GSK3β inhibitor BIO decreases mammosphere forming potential of
mesenchymal cells. A. MDA MB 231 reporter cells were grown in ultra-low attachments
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graphed. B. The heatmap summarizes the drug screen validation using mammosphere
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As expected BIO was able to inhibit the sphere forming potential of the MDA MB 231 reporter
cells but in order to validate this observation using multiple GSK3β inhibitors, the effect of 3
different GSK3β inhibitors on the sphere forming potential of all the three mesenchymal-like
human mammary cell lines, HMLE-Snail, HMLE-Twist and Sum159 was tested. The cells with
mesenchymal phenotype were plated for mammosphere assay. The control wells were treated
with DMSO (0.05%) and the experimental wells were treated with 3 different concentration of the
3 GSK3β inhibitors, BIO (0uM, 0.5uM, 1uM and 2uM), LiCl (0mM, 10mM, 20mM and 30mM) and
TWS119 (0uM, 0.5uM, 1uM and 2uM). The concentration of the drug that inhibited EMT (as
demonstrated in section 5B) and one concentration above and below that concentration were
used for the sphere assay. The media and the drugs were replenished every 2 days and at the
end of 10 days the number of mammospheres in each well were counted, plotted and analyzed
using GraphPad Prism. It was observed that all the three drugs BIO, LiCl and TWS119 were
capable of decreasing the mammosphere forming ability of all the three mesenchymal-like cells,
HMLE-Snail, HMLE-Twist and Sum159 (Figure 16).
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Figure 16 - GSK3β inhibitors decrease the mammosphere forming ability of the
mesenchymal cells in a dose dependent manner. HMLE Snail, HMLE Twist and Sum159
cells were grown in ultra-low attachments plates in mammosphere media for 10 days in the
presence of LiCl or TWS119. Number of mammospheres was counted and graphed.

While all the 3 GSK3β inhibitors tested were able to decrease the sphere forming ability of the
cells with mesenchymal properties with continuous treatment over 10 days, we had observed
earlier that GSK3β inhibitors are capable of inhibiting EMT within only 24hr of treatment. Thus,
the question arose as to whether 24hr treatment of the cells with mesenchymal phenotype was
sufficient to decrease their sphere forming ability, which is a surrogate assay to quantify the EMT-
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mediated CSC properties. To address this question, HMLE-Snail, HMLE-Twist and Sum159 cells
were treated with BIO, LiCl and TWS119 for 24hrs. After the treatment, the viable cells were
counted and plated for the mammosphere assay. 10 days following the plating, the
mammospheres were quantified and plotted using GraphPad Prism. We observed that just 24hr
pretreatment was sufficient to significantly decrease the sphere forming ability of HMLE-Snail and
Sum159 cells (Figure 17A). The HMLE-Twist cells seem to regain their CSC properties following
the withdrawal of the drugs. In order to rule out the possibility, that the decrease in the
mammosphere formation is due to the decrease in the proliferation rate of the cells following
treatment with GSK3β inhibitors, we treated all the 3 cell lines used in this study with all the 3
drugs and 10000 viable cells were plated in a 6-well plate. The proliferation rate of the cells
following the withdrawal of the drugs was monitored by counting the number of cells every day
for the next 3 days and generating a growth curve using this data (Figure 17B). We found that
there wasn’t a significant decrease in the proliferation rate of the mesenchymal-like cells lines
following treatment with the inhibitors as compared to the DMSO treated cells. BIO was the only
drug which decreased the proliferation rate following treatment.
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5E.

shRNA to GSK3β decreases the CSC properties of cells with mesenchymal

attributes.
GSK3β inhibitors were shown to be potent inhibitors of CSC properties of cells with mesenchymal
properties. Though multiple GSK3β inhibitors were tested for their ability to decrease the CSC
properties of multiple mesenchymal-like cells, using biological methods to achieve the same goal
strengthens the observations. Therefore, to examine if the biological silencing of GSK3β has the
same effect on the stem-like properties of the mesenchymal-like cells as the GSK3β inhibitors,
GSK3β was silenced in all the mesenchymal-like cells that have been consistently used in the
project. HMLE-Snail, HMLE-Twist and Sum159 were transduced with the shRNA to GSK3β in the
pGIPZ vector and the control cells were generated by transducing them with pGIPZ FF3 vector.
The FF3 targets the firefly luciferase gene which is not expressed in the human cells and therefore
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serves as a random target control. The transduced cells were selected based on their resistance
to puromycin and stable cell lines were generated. Protein and mRNA were extracted from these
cells and analyzed to see if the silencing of GSK3β using shRNA was successful. 2 different
shRNAs were used in order to rule out the possibility of off-target effects. The expression of
GSK3β was significantly decreased in all the cell lines tested at both the transcript and the protein
level following the transduction of the shRNA (Figure 18).
A
FF3
shGSK3β #1
shGSK3β #5

B
shGSK3β5
shGSK3β #5

shGSK3β1
shGSK3β #1

FF3
FF3

Sum159
shGSK3β #5
shGSK3β5

shGSK3β1
shGSK3β #1

FF3
FF3

HMLE Twist
shGSK3β #5

shGSK3β #1
shGSk3β1

FF3
FF3

HMLE Snail

GSK3β
Actin

Figure 18 – Knockdown of GSK3β by shRNA. shRNA targeting GSK3β suppressed the
expression of GSK3β at the transcript (A) and protein levels (B). Both the shRNAs knocked
down the expression of GSK3β in HMLE Snail, HMLE Twist, and Sum159.

The control cells and the mesenchymal-like cells with GSK3β shRNA were plated for the
mammosphere assay. At the end of 10 days, the mammospheres were quantified and plotted
using GraphPad Prism. As expected, suppressing GSK3β using shRNA resulted in a significant
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decrease in the sphere forming ability of the cells with mesenchymal and CSC properties (Figure

No.of sphere/1000 cells

19).
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p=0.001

p=0.005

shGSK3β
#1

shGSK3β
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Figure 19 – Knockdown of GSK3β decreases the mammosphere forming capability of the
mesenchymal cells. HMLE Snail, HMLE Twist, and Sum159 cells were stably transfected
with GSK3β shRNA, and grown in ultra-low attachments plates in mammosphere media for
10 days.

5F.

GSK3β knock-out MEFs show decreased ability to form spheres.

In addition to using shRNA, another biological means of achieving our goal is to knock out the
gene instead of suppressing its expression. Unlike shRNA which decreases the level of protein
expression, knocking out the gene completely eliminates the presence of the protein. A knockout
model was therefore used to assess the effect of GSK3β on the sphere forming ability of the
mesenchymal cells as a surrogate for CSC properties. Mouse embryonic fibroblasts (MEFs) which
are mesenchymal cells were used for this assay. Wild-type MEFs (MEF+/+) and MEFs with
GSK3β knocked out (MEF-/-) were obtained as a generous gift from Dr. Sarbosov at UT MD
Anderson Cancer Center. The proliferation of the 2 cell lines was assessed. Our results indicated
that there was no difference in the proliferation rate of the 2 cell lines. Both these cells were then
plated for the sphere-forming assay and their stem cell potential was evaluated. It was observed
that although there was no significant difference in the proliferation rate between the wild-type
and GSK3β knock-out MEFs, the knock out MEFs had significantly lower ability to form spheres
suggesting that they have reduced stem cell potential (Figure 20).
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Figure 20 – GSK3β knockout MEFs have decreased sphere forming potential, but not
proliferation, as compared to the wildtype MEFs. A. Mouse embryonic fibroblasts (MEFs) in
which GSK3β were knocked out were grown in ultra-low attachments plates in
mammosphere media for 10 days. B. Mouse embryonic fibroblasts (MEFs) in which GSK3β
were knocked out were grown for 4 days and growth was assessed on day 2, 3, and 4.

5G.

GSK3β inhibitors alter the CD24/44 profile of the mesenchymal-like cells

Apart from the mammosphere assay, the proportion of the stem-like cells in the mesenchymal
cell lines can also be determined by assessing the CD24/44 expression profile of the
mesenchymal-like cells. CD24 and CD44 are cell surface markers that are associated with more
differentiated state and stem-like state, respectively [67, 239, 240]. Therefore, HMLE-Snail,
HMLE-Twist and Sum159 cells were treated with all the 3 inhibitors and the control cells were
treated with DMSO. Following treatment, the cells were harvested and analyzed the CD24/44
profile of the mesenchymal-like cells. Unstained mesenchymal-like cells were used to set the
gates for CD24 and CD44 positivity. Cells with mesenchymal and stem-like properties are CD44
positive and CD24 negative which was observed in control treated samples. However, the treated
samples displayed a marked increase in the expression of CD24 indicating an increase in the
proportion of the differentiated cells in the mesenchymal-like cell lines (Figure 21).
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Figure 21 – GSK3β inhibitors increase the CD24 positive population in mesenchymal cells.
HMLE Snail, HMLE Twist, and Sum159 cells were treated with BIO, TWS119 or LiCl, and
assessed for the presence of CD44 and CD24 by flow cytometry.

To summarize, we observed that BIO was one of the small molecule inhibitors selected in the
screen that were able to inhibit the sphere forming potential of the mesenchymal-like MDA MB
231 reporter cells. Additionally, LiCl and TWS119 were also able to inhibit the sphere-forming
ability of the cells with mesenchymal phenotype. Further, suppressing GSK3β expression using
shRNA and GSK3β knockout MEFs elicited the same result of a significant decrease in the
sphere-forming potential of these cells. Examination of the CD24/44 profile of the mesenchymallike cells exposed to GSK3β inhibitors exhibited an increase population of CD24+ expressing cells
indicating the inhibition of GSK3β promotes a more differentiated phenotype in the mesenchymal–
like cells.
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5H.

Cells with mesenchymal phenotype are more sensitive to GSK3β as

compared to their epithelial counterparts.
From our analyses, we observed that the effect of GSK3β overexpression on overall survival of
patients was pronounced in the TNBCs. We also found a very significant upregulation of GSK3β
in the Richardson 2 data set which predominantly had EMT/CSC enriched tumor samples. This
observation suggested that there is an association between GSK3β, EMT and CSC properties
and prompting the question of whether the mesenchymal-like cells respond differentially to the
GSK3β inhibitors as compared to the cells with epithelial phenotype that have relatively reduced
CSC properties. For this, we subjected a panel of cell lines to the GSK3β inhibitors. The cell lines
selected for this assay were MCF10A cells (normal breast cell line), MCF7 (transformed epithelial
cell line) and Sum159 (EMT/CSC enriched cell line) [241-243]. Both MCF10A and MCF7 cells
share an epithelial phenotype whereas Sum159 cells clearly exhibit a mesenchymal phenotype
(Figure 22A). All the cell lines were treated with a range of concentrations of BIO (0uM, 0.1uM,
0.25uM, 0.5uM, 1uM, 2.5uM, 5uM, and 10uM), LiCl (0uM, 0.1uM, 0.5uM, 5uM, 10uM, 25uM and
50uM) and TWS119 (0uM, 0.1uM, 1uM, 5uM, 10uM, 25uM and 50uM) to assess the dose
response. The concentrations of the drugs were chosen such that there would be data points in
all the parts of the dose response curve. The treated cells were then subjected to a MTT assay.
The viability of the cells were calculated based on the absorbance of the wells treated with the
vehicle (DMSO). The viability of the cells treated with the vehicle control was considered as 100%
and the relative percentage viability of cells at different concentrations of the drug was calculated
and plotted using GraphPad Prism. For all the three drugs tested, the mesenchymal-like cells,
which possess some characteristics of basal subtype of breast cancer and TNBCs and express
higher levels of mesenchymal markers, were found to be more susceptible to GSK3β inhibitors
compared to their epithelial counterparts (Figure 22B).
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Figure 22 – Mesenchymal cells are more sensitive to GSK3β inhibitors as compared to
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MCF7 and Sum159 cells were treated with a dose range of the GSK3β inhibitors and the
viability was assessed and plotted using Graphpad.

In order to compare the ability of GSK3β inhibitors with other small molecule inhibitors (selected
from the small molecule screen) to differentiate between epithelial and mesenchymal cells, we
tested all the 11 drugs that were shortlisted from the screen. HMLE vector (a cell line with epithelial
properties expressing the empty vector pWZL) and HMLE-Snail (a cell line with mesenchymal
properties) were plated in 96 well plates and were treated with 6 different drug concentrations
(0uM, 0.5uM, 1uM, 5uM, 10uM, and 100uM). The viability of the cells were assessed using the
MTT assay and plotted using GraphPad Prism. We observed that including BIO, only PD168393
and CP-673451 were capable of significantly differentiating between epithelial and mesenchymal
cells. However, only BIO and CP-673451 selectively killed mesenchymal cells as compared to
epithelial cells (Figure 23A).

96

TSA

ACY
100

60

40

0

0

0
0

0
0

0
1

5

1

.5

0

1

1

0

0
0

0
1

5

PD

100

H M L E S n a il

H M LE

80

% V ia b ility

60

40

H M L E S n a il

100

H M L E S n a il
80

100

H M LE

60

40

H M LE

80

% V ia b ility

1

0

.5
0

CP

CUDC1

% V ia b ility

C o n c .( u M )

C o n c .( u M )

C o n c .( u M )

0

20

1

20

0

20

1

40

H M LE

5

40

60

H M L E S n a il

80

1

60

H M LE

% V ia b ility

% V ia b ility

% V ia b ility

A

H M L E S n a il
80

H M LE

.5

H M L E S n a il
80

0

100

100

0

TSU

A

60

40

20
20

H M L E S n a il

60

40

C o n c . (u M )

0

0
1

0

0

1

C o n c . (u M )

C o n c . (u M )

CABO

GW

100

1

0
0

0
1

5

1

0

1

.5

0

0
0

0
1

5

0

5

0

20

1

0

40

.5

20

0

20

60

0

40

H M LE

% V ia b ility

% V ia b ility

60

H M LE

80

80

H M LE

1

0
1

H M L E S n a il

H M L E S n a il
80

.5

0

100

100

0

1

0

1

B IO

Pano

100

0

5

0
0

0

0

5

1

1

0

.5
0

0
0

0
1

5

1

0

.5
0

1

C o n c .( u M )

C o n c .( u M )

C oSnCc h
.( u M )

% V ia b ility

1

0

0

0

.5

20

H M L E S n a il
H M LE

100

H M L E S n a il
H M LE

60

C o n c . (u M )

0
0

0
1

0

1

5

0
0

0

1

0

1

5

1

0

.5

20

0

1

40

20

.5

40

0

% V ia b ility

80

60

0

% V ia b ility

80

C o n c . (u M )

B

selective for
Mesenchymal cells

selective for
Epithelial cells
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PD on the other hand selectively inhibited epithelial cells as compared to mesenchymal-like cells.
The ratio of viability of HMLE vector to HMLE-Snail was calculated and a heatmap was generated
to summarize the findings of this experiment. When the drug selectively inhibits mesenchymal
cells, the viability of the epithelial HMLE vector cells is high and that of the HMLE-Snail cells is
low and the ratio calculated will be high. The color red stands for high value indicating that the
drug is selective for mesenchymal-like cells whereas blue stands for low value indicating that the
viability of the mesenchymal-like cells is higher. As is evident from the heatmap, BIO is capable
of selectively inhibiting mesenchymal-like cells as compared to their epithelial counterparts
(Figure 23B).

To further test if GSK3β inhibitors can indeed differentiate between epithelial and mesenchymallike cells, HMLER vector control and HMLER-Snail cells were used. HMLER cells are human
mammary epithelial cells that have been immortalized and transformed and HMLER-Snail cells
are HMLER cells in which Snail is overexpressed and hence these cells have mesenchymal
phenotype. The mesenchymal-like cells were labeled red. 1x106 cells of both red and green cells
were mixed and co-cultured (Figure 24A). The cells were treated with GSK3β inhibitors and
following treatment the proportion of viable green epithelial and red mesenchymal-like cells were
assess using flow cytometry. The percentage of cells was normalized to the percentage of
red/green cells in the DMSO treated sample to account for the differences in the proliferation rate
of the two cell lines. It was observed that there was a decrease in the proportion of the red
mesenchymal-like cells and an increase in the proportion of the green epithelial cells indicating
that the mesenchymal-like cells were selectively inhibited in the co-culture system (Figure 24B).
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HMLE-Snail (mesenchymal cells) labeled red were cultured together and were treated with
GSK3β inhibitors. Following the treatment the cells were harvested and subjected to FACS
analysis. B. Following treatment with GSK3β inhibitors, there were proportionally more
epithelial cells as compared to mesenchymal cells.

Summary – Aim 2: While Aim 1 established the basis of testing the potential of GSK3β inhibitors
as targets for inhibition of EMT/CSC enriched TNBCs, observations made in experiments
conducted to address Aim 2 indicate that GSK3β is indeed capable of inhibiting EMT and CSC
properties both of which are hallmarks of TNBCs. The high throughput screen performed to select
small molecules capable of inhibiting EMT in TNBC cell lines resulted in the identification of 11
candidate drugs of which one 2, CUDC-101 and BIO were validated as inhibitors of EMT. BIO, a
GSK3β inhibitor was selected as the lead compound as CUDC-101 has multiple different targets
and GSK3β was established as a potential target in Aim 1. In addition to BIO, 2 other GSK3β
inhibitors, LiCl and TWS119 were also able to inhibit EMT and EMT-endowed migratory potential
of the EMT/CSC-enriched cell lines. Further, GSK3β inhibition using small molecules, shRNA or
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GSK3β knockout in MEFs decreased the sphere-forming ability of mesenchymal-like cells.
Moreover, drugs tested also increased the expression of CD24 surface antigen on the
mesenchymal-like cells. We also observed that GSK3β inhibitors exerted selective inhibitory
effect on the mesenchymal-like cells as compared to their epithelial counterparts. Thus Aim 2
clearly demonstrates the ability of the GSK3β inhibitors to inhibit EMT and EMT-mediated
properties in the EMT/CSC enriched cells.
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Chapter 6 – Aim 3 – Test if GSK3β inhibitor can be effectively
used in vivo to target CSC-enriched breast cancers.
GSK3β inhibitor, TWS119 did not inhibit tumor size and metastatic potential of
mesenchymal cells in vivo.
Our observations suggested that GSK3β inhibitors were potent inhibitors of EMT and CSC
properties in vitro, and indeed inhibition of EMT and CSC properties has been shown to decrease
the tumorigenicity and metastatic potential of cancer cells in vivo [60]. Therefore, we used
luciferase labelled HMLER-Snail and 4T1 cells to test if GSK3β inhibitors were capable of
inhibiting tumorigenesis and metastasis in vivo. In both cell lines the GSK3β inhibitor TWS119
decreases EMT and CSC properties in vitro. Both these cell lines we injected into the mammary
fat pad of mice and were allowed to grow until a palpable tumor was observed. Once a palpable
tumor was detected which was in ~1 week for HMLER-Snail and ~4 days for 4T1, the mice were
randomized into 2 groups. One group was treated with vehicle (DMSO) and the other with
30mg/Kg of TWS119 which was administered intraperitoneally every other day. TWS119 was
used for the in vivo experimentation as it is a highly specific drug for GSK3β and the dosage and
route of administration was decided based work of Gattinoni et.al. [244]. Tumor progression was
monitored by imaging the mice weekly for luciferase activity (Figure 25, 26). The 4T1 experiment
was terminated because the tumor burden exceeded the allowed size of 2 cm in diameter prior to
the completion of the experiment. HMLER-Snail experiment had to be terminated due to scarring
of the site of injection that made further administration of the drug difficult.
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Figure 25 – GSK3β inhibitor TWS119 with HMLER-Snail cells in vivo. A and D. 1x106
HMLER-Snail cells were injected orthotopically and their progression in was monitored by
imaging for the luciferase signal and the luminescence was assessed. B and D. At the end
of the experiment, the animals were sacrificed and the tumors were harvested and diameter
was quantified. C and D. At the end of the experiment, the animals were sacrificed and the
lungs were harvested and nodules on the lungs were quantified.
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The animals were sacrificed and the primary mammary tumor and lungs (to check for distant
metastasis) were isolated and fixed for immunohistochemical analysis. The tumor size was
measured and lung nodules counted. There was no significant difference in the size of tumors
and the number of metastatic nodules in the lungs between the vehicle-treated set and the
TWS119-treated set in both the 4T1 and the HMLER-Snail experiments (Figures 25 B,C&D, 26
B,C&D). This was in line with the observation that there was no significant difference in the photon
counts between the TWS119 treated and vehicle treated mice in both these experiments (Figures
25 A&D, 26 A&D). One of the possible reasons for the inability of TWS119 to inhibit tumorigenesis
and metastasis, could be that the drug did not reach the tumor. In order to test this hypothesis,
immunohistochemistry (IHC) was performed to assess the expression of β-Catenin, FOXC2 and
fibronectin. If the drug reached the target, there would be an accumulation of β-catenin in the
nucleus indicating active Wnt signaling and inactive GSK3β, and if the drug was able to inhibit
EMT in vivo, the expression of FOXC2 and fibronectin would be lower in the treated tumors as
compared to the control treated tumors. The staining showed that there was no difference in the
expression of β-catenin, FOXC2 or fibronectin between the treated and the untreated tumors
indication that the drug was unable to reach its target (Figure 27).

Summary – Aim3: Aim3 was performed to assess the efficacy of GSK3β inhibitors to inhibit the
tumor progression of EMT/CSC-enriched breast cancer cells in vivo. However, due to the
concentration of the drug used or due to the chosen method of application, we observed no
significant decrease in the tumor size and metastatic potential of the EMT/CSC-enriched HMLERSnail and 4T1 cells with TWS119 treatment.
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Figure 26 – GSK3β inhibitor TWS119 with 4T1 cells in vivo. A and D. 10000 4T1 cells were
injected orthotopically and their progression in was monitored by imaging for the luciferase
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104

Control

TWS119

β-Catenin

Fibronectin

FOXC2

Figure 27 – Immunohistochemistry of xenograft tumors treated with TWS119. HMLER-Snail
tumors were fixed and immunohistochemistry was performed for β-Catenin, Fibronectin and
FOXC2. We observed no difference in the expression of these proteins between the treated
and the untreated tumors. Images were taken at 20x.
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Chapter 7 - Conclusions
This study was performed to investigate the role of GSK3β as a potential druggable target to
inhibit the progression of EMT/CSC-rich TNBCs. Therefore, publicly available databases were
analyzed to determine if GSK3β is indeed upregulated in breast cancers and the analysis revealed
that GSK3β was significantly upregulated in breast cancer tissues as compared to the normal
mammary tissues in the Ma, Richardson 2 and TCGA datasets. Besides being expressed at
higher levels in breast tumors, KMPlotter analysis also demonstrated that the elevated levels of
GSK3β in TNBCs significantly correlates with worse overall survival in these patients. These
findings suggested a possible role for GSK3β in the progression of TNBCs.

TNBCs are EMT/CSC enriched cancers and as mentioned in Chapter 1, EMT and EMT-endowed
CSCs are the cause of tumor recurrence, chemoresistance and higher metastatic potential of
TNBCs. Therefore, inhibition of the EMT/CSC properties could be a feasible means of preventing
TNBC-related fatality. In order to identify small molecule inhibitors capable of inhibiting EMT in
TNBCs, TNBC representative cell line MDA MB 231 (modified to express Zeb1 and E-cadherin
reporter) was used to perform a high-throughput drug screen. Among the ~1300 drugs tested, 11
drugs were identified as potential inhibitors of EMT. Upon validation using FACS, only 2 drugs
were observed to successfully inhibit EMT in the TNBC cell line. Of the 2 drugs that were selected
from the screen GSK3β inhibitor BIO was finalized as the lead candidate based on our analysis
of the patient data and on the fact that CUDC-101 has multiple different targets. To rule out the
possibility that this ability of inhibiting EMT is unique to BIO, 2 other GSK3β inhibitors, LiCl and
TWS119 were also tested for their ability to inhibit mesenchymal properties of 3 different cell lines
with EMT/CSC properties (HMLE-Snail, HMLE-Twist and Sum159). Both western blot analysis
and qRT-PCR analysis demonstrated a decrease in the expression of mesenchymal markers and
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increased expression of epithelial markers indicating an effective inhibition of EMT by the GSK3β
inhibitors. GSK3β inhibitors were also observed to decrease the EMT-mediated migratory
properties of the EMT/CSC-enriched cell lines (HMLE-Snail, HMLE-Twist and 4T1) and this effect
of GSK3β inhibitors could be attributed to the inhibition of EMT at the wound edge in addition to
the other well-established mechanisms.

It is well-known that EMT bestows CSC properties on cancer cells. As GSK3β inhibitors were
effective in inhibiting EMT, the obvious next question was to test if GSK3β inhibitors were capable
of inhibiting the sphere-forming potential of the TNBC cell line (MD MB 231 reporter cells). Of the
11 drugs that were selected from the drug screen, BIO was one of the drugs capable of decreasing
the sphere-forming ability of the TNBC cell line. Not only BIO, but the other 2 drugs LiCl and
TWS119 and shRNA to GSK3β were also able to decrease the sphere-forming potential of the
mesenchymal-like cells. Additionally, MEFs in which GSK3β was knocked out also lost their ability
to form spheres. Further, the 3 GSK3β inhibitors tested were also able to increase the proportion
of CD24 expressing cells in the mesenchymal-like cell lines. All these observations taken together
indicate that GSK3β inhibitors decrease the CSC properties and increase the proportion of
differentiated population of the mesenchymal-like cell lines.

As the GSK3β inhibitors were shown to inhibit EMT and EMT-mediated CSC properties, which
are characteristic of the mesenchymal-like cell lines, it was intriguing to test if the GSK3β inhibitors
exerted selective inhibitory effect on EMT/CSC enriched cells as compared to their epithelial
counterparts. Of the 11 drugs isolated in the screen, BIO was one of the 2 drugs capable of more
potently inhibiting mesenchymal-like HMLE-Snail cells as compared to the epithelial HMLE-vector
cells. All 3 GSK3β inhibitors (BIO, LiCl and TWS119) selectively inhibited mesenchymal-like cells
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(Sum159) as compared to epithelial (MCF7) or normal-like (MCF10A) breast cell lines. In addition,
in co-culture experiments, all 3 GSK3β inhibitors selectively inhibited mesenchymal-like (HMLERSnail) cells as compared to the epithelial (HMLER) cells.

Based on our in vitro observations that GSK3β inhibitors effectively inhibited EMT, and EMTmediated enhanced migratory and sphere-forming potential and selectively inhibited
mesenchymal-like cells, we decided to test GSK3β-specific inhibitor (TWS119) in vivo. However,
at the dosage used and with the route used to administer the drugs, no inhibitory effect was
observed on the tumor size and metastatic potential of EMT/CSC-enriched cell lines. IHC analysis
indicated that there was no inhibition of GSK3β based on the observation that there was no
difference in the level of expression and localization of β-catenin between the treated and the
untreated tumors. Therefore, the drug dosage and administration has to be modified to ensure
that the drug is able to effectively inhibit GSK3β in vivo.
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Chapter 8 – Discussion and future directions
Since the discovery of Wnt signaling and its role in cancer, there has been an extraordinary
emphasis on the association of the Wnt signaling with EMT, CSC properties and consequently on
metastasis of cancers. However, this eclipses the roles played by other equally important players
in the field. In this study we focused on the role of GSK3β and its importance as a prognostic
factor and therapeutic target in breast cancer.

In our study, we found that high expression of GSK3β correlated with the poor survival of breast
cancer patients. This was surprising as GSK3β is a negative regulator of Wnt signaling and
therefore the presence of high levels of GSK3β would indicate an inactive Wnt signaling which
would be considered as a good prognostic factor, considering the known effect of Wnt signaling
on CSCs. Data mining also revealed that GSK3β is indeed expressed in elevated levels in breast
tumor samples as compared to normal breast tissue.

Using multiple small molecule inhibitors of GSK3β, we have demonstrated that inhibition of
GSK3β significantly decreased the expression of FOXC2 and fibronectin, both of which are robust
markers of the mesenchymal phenotype. The decrease in expression of FOXC2 protein clearly
explains the loss of CSC properties in the mesenchymal-like cells, as it has been previously
illustrated that FOXC2 is essential for the CSC properties of cancer cells [67]. Additionally, under
certain circumstances, GSK3β is known to be a positive regulator of NFκB, which in turn, has
been demonstrated to promote FOXC2 expression and function [245, 246]. Therefore,
pharmacological inhibition of GSK3β also promises to downregulate NFκB-mediated upregulation
of FOXC2, thereby providing the means of targeting multiple pathways of tumor progression and
metastasis [208]. In depth understanding of how GSK3β functions and is regulated sheds light on
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how complex this protein is. For example, when we treat with a small molecule inhibitor, there is
no way of pinpointing the pool of GSK3β that is majorly affected or if the overall function of GSK3β
in all the pools is uniformly inhibited. There is also a dearth of knowledge regarding the flux of
GSK3β between the different pools. Therefore, it is impossible to predict if one pool of GSK3β is
maintained at the cost of the other pools thus allowing certain functions of GSK3β to proceed
uninterrupted while compromising on the functions that are less vital to the cell in a particular
context. Therefore, while it is easy to just examine the role of a molecule with regard to a single
signaling pathway or cell type, looking at the bigger picture is essential to give context to the
findings.

Again contrary to the expectations, we found that inhibition of GSK3β clearly inhibited the CSC
properties of the mesenchymal-like cells, which is evident in both the increase in the expression
of differentiation-related cell surface marker CD24 and the decrease in the stem cell-related
sphere forming ability of the cells. This emphasizes the fact that these effects of GSK3β inhibition
could be due to the effect of the inhibitors on the Wnt-independent activity of the GSK3β. GSK3β
is a highly versatile kinase with several targets involved in different pathways which regulate each
other and thus making GSK3β a pivotal player in regulating the different pathways. Therefore, the
effect elicited by GSK3β inhibitors need not primarily be equivalent to the activation of Wnt
signaling pathway. The different pathways that could be affected depend upon the regulation of
the downstream molecules which determine the direction of flow of information.

Along with the inhibition of the CSC properties, the GSK3β inhibitors also significantly decrease
the migration of the mesenchymal-like cells, which indicates a reduction in the aggressive
metastatic potential of these cells. There have been other publications demonstrating that
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inhibition of GSK3β inhibits the migratory properties of the cells and this effect of GSK3β has been
attributed to its effects on molecules such as Rac and Rock [236]. However, we show additional
means by which GSK3β could alter the migration of the cells. In HMLE cells, we show that
migration of the cells is accompanied by the upregulation of FOXC2 at the migratory front of the
cells. In the presence of the GSK3β inhibitors, this upregulation of FOXC2 is prevented which
adds to the inhibitory effect of GSK3β inhibitors.

One of the main challenges in this study was the fact that shRNAs to GSK3β were not able to
recapitulate the downregulation of mesenchymal markers effected by the small molecule
inhibitors. This could be attributed to the fact the small molecule inhibitors inhibit GSK3β to a
greater extent than the inhibition by the shRNA, and that the inhibition by the shRNA was enough
to affect the sphere forming ability of the cells, but not sufficient to suppress the expression of the
mesenchymal markers. In order to address this issue, GSK3β knockout MEFs were used and we
were able to demonstrate a decrease in the expression of FOXC2, but it was difficult to use
fibroblasts to study alterations in EMT. Another means of testing could be to use CRISPR
technology to delete GSK3β which would be superior because it would deletion of the GSK3β
gene resulting in the abrogation of the protein. We have not yet tested this approach. While both
knockdown of GSK3β as in the MEF and the use of CRISPR are good means for identifying the
role of GSK3β in cell lines, this method will be hard to achieve in patients. Also GSK3β is a
multifunctional molecule with many reported (apparently unrelated) functions. Another
explanation for this discrepancy could be the fact that the small molecule inhibitors inhibit both
GSK3β and GSK3α, which have some redundant functions. However, attempts to create double
knockdowns failed as cells most likely did not survive in the absence of such vital kinases. It is
interesting to note that shRNA to GSK3β did significantly decrease the CSC properties of the cells
without affecting their EMT properties. This leads to another interesting theory that GSK3β could
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be the point of bifurcation between EMT and CSC properties which are currently considered to
be the 2 sides of the same coin. The ultimate goal of this study is to find a means of targeting
tumor progression and metastasis. Due to the importance of Wnt signaling in tumor progression
and metastasis, efforts are ongoing to design Wnt inhibitors that can effectively inhibit metastasis.
However, these studies are in their infancy and have to overcome several obstacles to be
successful anticancer drugs.

The most striking finding in this study is that the GSK3β inhibitors have a potent inhibitory effect
on mesenchymal-like cells (Sum159) but not on epithelial (MCF7) or normal-like (MCF10A) breast
cancer cell lines. It will be important for future studies to decipher the molecular mechanism
underlying this differential activity. One way to address this issue would be to perform a microarray
to compare the changes in the gene expression profile of the cells following treatment with GSK3β
inhibitors. This could provide insight into which pathways are differentially altered between the
normal-like, epithelial and mesenchymal-like breast cancer cell lines.

On the other hand the GSK3β inhibitors have been widely used in the treatment of psychiatric
disorders and their effect and side effects have been well documented. GSK3β is a vital molecule
that serves as a hub for several signaling pathways. Therefore, the small molecule inhibitors of
GSK3β can be used to efficiently target and modulate several different pathways and significantly
hinder the proliferation and metastasis of cancer cells. Despite the existence of controversial
literature suggesting a potential role of GSK3β as a tumor suppressor in breast cancer based on
in vitro studies, there is paucity of in vivo data to substantiate this claim [192, 247, 248]. Knowing
how diverse and heterogeneous cancer is, even breast cancer cannot be classified as a single
disease. Therefore, it would be unwise to classify a ubiquitous and multifunctional kinase such as
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GSK3β as a tumor promoter or suppressor. Additionally the strong correlation between the
expression of GSK3β and poor prognosis in breast cancer patients is in itself a strong proponent
of the therapeutic use of GSK3β inhibitors in addition to the standard-of-care treatment currently
available for the treatment of breast cancers. One of the other main concerns is that inhibition of
GSK3β in patients would lead to the activation of Wnt, a tumor promoter and hyperactivation of
Wnt signaling pathway in breast cancer is a well-established fact. Therefore, inhibition of GSK3β
cannot further activate the already activated system. Therefore, treating breast cancers with
hyperactivated Wnt signaling should manifest no effect on the Wnt signaling pathway but on the
other pathways in which GSK3β is involved. There are also reports to show that there is no
evidence of increased tumor incidence in patients chronically treated with lithium for their
psychiatric disorders [249].

Contrary to expectation, our in vivo experiments to test the efficacy of the GSK3β inhibitors were
not conclusive regarding the efficacy of the drug. It is possible that the injected drug did not reach
the intended target. Therefore, we performed IHC to test if this hypothesis is true. The tumors and
the lungs isolated from the animals were fixed and embedded and stained to determine if GSK3β
was indeed inhibited in the tumors or if the drugs did not reach the target. The HMLER-Snail tumor
sections were stained for β-Catenin, FOXC2 and fibronectin. If the drug successfully reached the
target and inhibited GSK3β, we would expect to see a significant increase in the expression and
nuclear localization of β-Catenin and based on the in vivo experiments, a decrease in the
expression of FOXC2 and fibronectin. However, we observed no difference in the levels of
expression of β-Catenin between the GSK3β inhibitor treated and the control treated tumors
indicating that the drug did not reach its target or did not exert its effect on the tumor cells.
Therefore, the experiment did not give the expected results. Additionally, our observations with
regards to the 4T1 experiment indicate that continued treatment could have attenuated the ability
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of the breast cancer cells to metastasize. However, this could not be tested due to the morbid
tumor volumes in case of 4T1 cell lines and due to the toxic effect of DMSO at the site of injection.

One of the main challenges is the lack of in vivo studies using TWS119. As a result, there is not
enough published data available to determine the correct dosage and treatment regime.
Therefore, more pharmacological studies are required to optimize the treatment plan for testing
the efficacy of the drug to inhibit tumorigenesis and metastasis of breast cancer. Considering the
ability of GSK3β inhibitors to specifically target mesenchymal-like cells with CSC properties, the
GSK3β inhibitors may be better suited for combination treatments.

A key future direction is to identify chemotherapeutic agents whose efficacy can be improved by
the addition of GSK3β inhibitors to the treatment regimen. As the GSK3β inhibitor from Eli Lily
(LY2090314) is FDA approved and in clinical trial, we have decided to add this drug to our studies
[200]. LY2090314 has been shown to increase the potency of platinum drugs [200]. Therefore,
platinum drugs will be one of the primary candidates to be tested for combination treatment with
GSK3β inhibitors in TNBCs. The next step will be to determine the dosage and test the efficacy
of the drug in vivo. In case of LY2090314, there have been several in vivo studies performed in
melanoma models [250]. Therefore as the treatment parameters have been well established, it
could therefore serve as the starting platform to test this drug in vivo. Based on these new data,
we aim to design combination treatment regimens for treating orthotopic TNBC mouse models.
Additionally, we have access to several TNBC patient-derived xenograft (PDX) models through
our collaborators and these will serve as perfect models to test the combination treatments as
they are truer representatives of the disease heterogeneity than cell lines. The subsequent goal
would be to study the pathways that are differentially altered between the epithelial and
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mesenchymal-like cells following treatment with GSK3β inhibitors using microarray or RNAseq
techniques.

The primary goal of this study was to identify novel druggable targets to treat TNBCs which
currently lack targeted therapies. This study serves as a preliminary indicator that there is more
promise in using GSK3β inhibitors if close consideration is given to the pleiotropic signaling
cascades it influences rather than as a mere modulator of a single signaling cascade which is the
Wnt signaling pathway. Our goal is to continue our efforts to establish a probable mechanism of
action for the effect to GSK3β inhibitors in the inhibition of EMT and CSCs and to define a viable
and potent combination treatment for TNBCs.
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